Document:

Ex-10.37 Collaboration and License Agreement

 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Exhibit 10.37

COLLABORATION AND LICENSE AGREEMENT

     THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made effective as of the 7th day
of September, 2006 (the “Effective Date”) by and between GTx, Inc., a Delaware corporation having
its principal place of business at 3 North Dunlap St., Memphis, Tennessee 38163 (“GTx”) each on
behalf of itself and its Affiliates and Ipsen Limited, a company organized under the laws of
England and Wales, with its principal place of business at 190 Bath Road, Slough SL1 3XE, United
Kingdom (“Ipsen”), each on behalf of itself and its Affiliates. GTx and Ipsen are sometimes
referred to herein individually as a “Party” and collectively as the “Parties”, and references to
“GTx” and “Ipsen” shall include their respective Affiliates.

RECITALS

     Whereas, Ipsen is a multinational healthcare company with research, development and
marketing activities, which desires to obtain additional potential drug products for the prevention
of prostate cancer, the treatment of complications arising from androgen deprivation therapy for
advanced prostate cancer, and other possible indications;

     Whereas, GTx is a men’s health biotech company, which is developing certain compounds
to prevent prostate cancer and treat complications arising from androgen deprivation therapy,
including Acapodene®;

     Whereas, GTx is conducting two clinical studies of Acapodene® for two separate
indications in the United States (“US”) under special protocol assessments (“SPA”) with the US Food
and Drug Administration: (a) a Phase III clinical trial of a 20 mg dose of Acapodene for the
prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (the “PIN
Trial”), and (b) a Phase III clinical trial of a 80 mg dose of Acapodene for the prevention of bone
fractures and serious side effects of androgen deprivation therapy in men with prostate cancer
(the “ADT Trial”);

     Whereas, GTx is the exclusive licensee of the compound, Toremifene, the active
ingredient of Acapodene, from Orion Corporation, a Finnish pharmaceutical company (“Orion”), and
the exclusive licensee from the University of Tennessee Research Foundation (“UTRF”) of certain
methods of use patents and patent applications claiming or covering Toremifene and other selective
estrogen receptor modulators for the treatment of high grade prostatic intraepithelial neoplasia
and the prevention of prostate cancer; and

     Whereas, GTx desires to exclusively sublicense to Ipsen, and Ipsen desires to
exclusively sublicense from GTx, rights under GTx’s license agreements from Orion and UTRF

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 1.

 

to Acapodene for all human uses within the European Union (and certain other countries) except
for the treatment and prevention of breast cancer, in accordance with the terms and provisions of
this Agreement.

     Now, Therefore, in consideration of the foregoing premises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties agree as follows:

ARTICLE I

DEFINITIONS

     The following terms shall have the following meanings as used in this Agreement:

     1.1 “Active Ingredient” means the material(s) in a pharmaceutical product which provide its
pharmacological activity (excluding formulation components such as coatings, stabilizers or
controlled release technologies).

     1.2 “ADT” means androgen deprivation therapy.

     1.3 “ADT Indication” means the treatment or prevention of the side effects of ADT in men with
prostate cancer.

     1.4 “ADT Trial” shall have the meaning set forth in the Recitals.

     1.5 “Affiliate” means an entity that, directly or indirectly, through one or more
intermediaries, controls, is controlled by or is under common control with GTx or Ipsen, as
applicable. For the purposes of this Section 1.5, the term “control” (including, with correlative
meanings, the terms “controlled by” and “under common control with”) as used with respect to a
Party, shall mean the possession, directly or indirectly, of the power to direct, or cause the
direction of, the management or policies of such person or entity, whether through the ownership of
voting securities, by contract or otherwise.

     1.6 “Agreement” shall have the meaning set forth in page one.

     1.7 “Bundled Product” means any combination of a Licensed Product and another pharmaceutical
product that is not a Licensed Product where such products are not formulated together but are sold
together for a single invoiced price.

     1.8 “Business Day” means a day on which banking institutions in New York (USA) and London
(United Kingdom) are open for business.

     1.9 “Clinical Studies” means human studies designed to measure the Safety, efficacy,
tolerability, pharmacokinetics and appropriate dosage of a Licensed Product. Clinical Studies
shall include, without limitation: (a) the PIN Trial and the ADT Trial ; (b) any other clinical
studies that GTx determines is necessary or useful to conduct in the GTx Territory for the Initial
Products to achieve or maintain Regulatory Approvals in the ADT Indication or the

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 2.

 

PIN Indication, including a Phase IIIB Clinical Trial and/or Phase IV Clinical Trial, as
defined herein; or (c) any clinical studies that Ipsen determines is necessary or useful to conduct
in the European Territory for the Initial Products to achieve or maintain Regulatory Approvals in
the ADT Indication or the PIN Indication.

     1.10 “Combination Product” means any pharmaceutical product that consists of a Licensed
Product that also contains another Active Ingredient that is not Toremifene.

     1.11 “Commercialization Activities” means activities relating to the marketing and sale of a
Licensed Product.

     1.12 “Competing Product” shall mean [ * ].

     1.13 “Confidential Information” shall have the meaning set forth in Section 8.1 of this
Agreement.

     1.14 “Control” or “Controlled” means the possession by a Party of the right to grant a license
or sublicense to intangible property rights (including patent rights, know-how and/or trade secret
information), and the right to provide access to or cross-reference to regulatory filings or other
data or information, or the terms of any pre-existing agreement or other arrangement with any Third
Party. “Control” expressly includes the right of ownership, in whole or in part, unless the Party
having such right is restricted by contract or under law from granting such a license, access or
right to reference.

     1.15 “Cost of Goods Sold” or “COGS” means the sum of (a) the Supply Price, (b) all payments
made by Ipsen to Third Party contract manufacturer(s) for supply and delivery to Ipsen of fully
packaged and labeled Licensed Products and/or any direct costs incurred internally by Ipsen for the
packaging and labeling of the Licensed Products, (c) Royalty Payments to GTx for such Licensed
Products, (d) Third Party royalty payments, and (e) any other customary and reasonable overhead
costs actually incurred in, and reasonably allocable to, the procurement of Licensed Product,
including: import and export duties; applicable taxes assessed on the purchase of such material;
port fees and storage fees; shipping and handling; quality control; and quality assurance. The
methodology for calculating Cost of Goods Sold shall be consistent with Ipsen’s accounting policies
and procedures for other products and shall be consistent from year-to-year.

     1.16 “Cover” shall mean with respect to Patents that, but for a license granted to a Party
under such Patents, the manufacture, use, offer for sale, sale or importation of such product would
infringe a Valid Claim.

     1.17 “Data and Market Protection” means, as to a given country, for the Licensed Product and a
given time period, that (a) no Third Party has the right to cross-reference the data generated for
the obtaining of the Regulatory Approval of a Licensed Product in a given Indication in order to
obtain a Regulatory Approval for a Generic and (b) no Third Party has the right to commercialize a
Generic in a given Indication in such country.

     1.18 “Developing Party” shall have the meaning ascribed to it in Section
4.3(c)(i) of this Agreement.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 3.

 

     1.19 “Dominating Patent” means an unexpired patent of a Third Party which has not been
invalidated by a court or other governmental agency of competent jurisdiction and which would be
infringed by the use, manufacture, sale or import of the Licensed Product under this Agreement.

     1.20 “Drug Approval Application” means an application for Regulatory Approval required before
commercial sale or use of a product as a drug in a regulatory jurisdiction.

     1.21 “Effective Date” shall have the meaning set forth on page one of this Agreement.

     1.22 “Election” and “Election Fee” shall have the meaning set forth in Section 4.2(e) of this
Agreement.

     1.23 “EMEA” means the European Medicines Agency or any successor thereto.

     1.24 “EU” means the European Union and shall include Austria, Belgium, Denmark, Finland,
France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, Sweden,
United Kingdom, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland,
Slovakia, Slovenia, and any such other country or territory that may become part of the European
Union after the Effective Date.

     1.25 “European Territory” means the EU, Switzerland, Norway, Iceland and Lichtenstein and the
Commonwealth of Independent States (which for purposes hereof means Russia, Belarus, Ukraine,
Moldova, Kazakhstan, Azerbaijan, Armenia, Kyrgyzstan, Uzbekistan, Tajikistan and Georgia).

     1.26 “Executive Officers” means the Chief Executive Officer of GTx (or another senior officer
of GTx designated by GTx’s Chief Executive Officer) and the Chief Executive Officer of Ipsen (or
another senior officer of Ipsen designated by the Chief Executive Officer of Ipsen).

     1.27 “Fareston” means the Orion drug product, containing Toremifene as the Active Ingredient,
that is promoted in the US under the brand name “Fareston” by GTx, and in the rest of the world by
Orion or its Affiliates, sublicensees and distributors for the treatment and prevention of advanced
breast cancer.

     1.28 “FDA” means the United States Food and Drug Administration or any successor agency
thereto having the administrative authority to regulate the marketing of human pharmaceutical
products or biological therapeutic products, delivery systems and devices in the United States of
America.

     1.29 “FDC Act” means the Federal Food, Drug and Cosmetic Act, as amended from time to time.

     1.30 “FTE” means the equivalent of the work of one (1) employee full time for one (1) calendar
year (consisting of at least a total of [ * ] of work pursuant to the development activities with
respect to Licensed Products. Any employee who devotes less than [ * ] shall be

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 4.

 

treated as an
FTE on a pro-rata basis calculated by dividing the actual number of hours worked during such
calendar year by [ * ].

     1.31 “FTE Cost” means the cost to GTx of its scientific, technical, regulatory or clinical
personnel directly dedicated to the execution of the development activities (excluding
administrative personnel), and shall be calculated by multiplying the FTE Rate by the number of
FTEs.

     1.32 “FTE Rate” means, as of the Effective Date, [ * ] per FTE. Such rate shall be adjusted
annually to reflect the total percentage increase in the U.S. Consumer Price Index for the time
period from the Effective Date until the time at which such index was recalculated at the time of
adjustment (with the first adjustment to occur [ * ], with subsequent adjustments on each
anniversary thereof). For clarity, said rate includes charges for standard and/or existing lab
supplies and equipment and customary business expenses such as insurance.

     1.33 “Generic” means any pharmaceutical product sold by a Third Party, not authorized by
Ipsen, an Affiliate or sublicensee, that contains Toremifene as an Active Ingredient and which can
be substituted by the prescriber or dispenser for the Licensed Product for use in the Indications.

     1.34 “GTx Initial Development” means Initial Development by GTx of the Initial Products for
the ADT and PIN Indications in the GTx Territory.

     1.35 “GTx Initial Development Budget” and “GTx Initial Development Plan” shall have the
meaning ascribed to it in Section 4.2 (a)(i) of this Agreement.

     1.36 “GTx Invention” means any Invention made solely by GTx as from the Effective Date
including a GTx Product Improvement.

     1.37 “GTx Know-how” means Information which is within the Control of GTx and is reasonably
necessary for the development, import, offer for sale, use or sale of the Licensed Products in the
Indications within the European Territory. GTx Know-how shall include Information obtained by GTx
under the GTx Licenses, GTx Inventions, GTx Product Improvements, and GTx’s interest in any Joint
Inventions. Notwithstanding anything herein to the contrary, GTx Know-how shall exclude GTx
Patents.

     1.38 “GTx Licenses” means the Orion License and the UTRF License.

     1.39 “GTx Patent” means all Patents Controlled by GTx in the European Territory which Cover
the Licensed Products. A list of the GTx Patents identified as of the Effective Date is attached
hereto as Exhibit A. GTx Patents include without limitation GTx’s interest in any Joint Patents
and Patents relating to GTx Inventions.

     1.40 “GTx Product Improvement” means any Product Improvement
Controlled by GTx as from the Effective Date.

     1.41 “GTx Territory” means the United States and all other parts of the world, except
the
European Territory.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 5.

 

     1.42 “IND” shall mean (a) an Investigational New Drug Application as defined in the United
States Food, Drug and Cosmetic Act and applicable regulations promulgated thereunder by the FDA, or
(b) the equivalent application to the equivalent agency in any other country or group of countries,
the filing of which is necessary to commence clinical testing of a pharmaceutical product in humans
in a particular jurisdiction.

     1.43 “Indication” means any disease or condition in humans, except the treatment and
prevention of breast cancer. The Parties expressly acknowledge that the use of Licensed Products
for any disease or condition in animals is excluded from the scope of this Agreement.

     1.44 “Information” means techniques and data relating to Toremifene, Initial Products or
Licensed Products including (but not limited to) inventions, practices, methods, knowledge,
know-how, skill, experience, test data including Pre-Clinical Studies and Clinical Studies test
data, analytical and quality control data, statistical analyzing plan (SAP), marketing, pricing,
distribution, cost, sales data or descriptions, and compounds, compositions of matter, assays and
biological materials related thereto.

     1.45 “Initial Development” means activities relating to obtaining Regulatory Approval of the
Initial Products in the ADT Indication and the PIN Indication, in each of GTx’s and Ipsen’s
respective territories. Initial Development includes, but is not limited to, Pre-Clinical Studies,
Clinical Studies and regulatory affairs activities.

     1.46 “Initial Development Expenses” means the expenses incurred by a Party or for its account
by a Third Party which are consistent with a Initial Development Plan and Initial Development
Budget and are incurred in connection with Pre-Clinical and Clinical Studies (whether conducted
internally or by a Third Party, individual investigators or consultants, including Phase IIIB
Clinical Trials), toxicological, pharmacological, pharmacokinetic, metabolic, analytical,
formulation, chemical studies, and qualification and validation batches of product, as required by
the Regulatory Authorities for the purpose of obtaining Regulatory Approval of the Initial Product,
and costs (and related fees) for preparing, submitting, reviewing or developing data or information
for the purpose of submission to a Regulatory Agency to obtain and/or maintain Regulatory Approval
of the Initial Product in the PIN and the ADT Indication.

     1.47 “Initial Development Plan” shall mean either Ipsen Initial Development Plan or GTx
Initial Development Plan.

     1.48 “Initial Election Period” shall have the meaning ascribed to it in Section 4.2(e)(iii) of
this Agreement.

     1.49 “Initial Products” means the Licensed Products currently being studied in
the PIN Trial and the ADT Trial under the appropriate dosages.

     1.50 “Invention” means any invention relating to Toremifene or Licensed Product (whether
patentable or not and including but not limited to Know-How) including without

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 6.

 

limitation a Product
Improvement made by the Parties after the Effective Date during the course of, in furtherance of,
and as a direct result of the activities of the Parties hereunder.

     1.51 “Ipsen Initial Development” means all Initial Development by Ipsen of the Initial
Products for purposes of obtaining Regulatory Approval within the European Territory for the ADT
Indication and the PIN Indication.

     1.52 “Ipsen Initial Development Plan” shall have the meaning ascribed to it in Section 4.2
(a)(ii) of this Agreement

     1.53 “Ipsen Invention” shall mean any Invention made solely by Ipsen as from the Effective
Date including an Ipsen Product Improvement which development, manufacture, import, sale and use is
Covered by a Valid Claim of GTx Patents.

     1.54 “Ipsen Know-how” means Information relating to the Licensed Product, including Ipsen
Inventions, Ipsen Product Improvement and Ipsen’s interest in Joint Inventions which is within the
Control of Ipsen and which is reasonably necessary for the development, import, offer for sale, use
or sale of the Licensed Products in the Indications within the GTx Territory.

     1.55 “Ipsen Patents” means any Patents relating to an Ipsen Invention which Patents are owned
or Controlled by Ipsen. Ipsen Patents shall include Ipsen’s interest in Joint Patents.

     1.56 “Ipsen Product Improvement” means a Product Improvement Controlled by Ipsen as from the
Effective Date and which development, manufacture, import, sale and use are Covered by a Valid
Claim of GTx Patents.

     1.57 “Joint ADT Initial Development Expenses” shall have the meaning set forth in Section
4.2(f)(iii) of this Agreement.

     1.58 “Joint Development Committee” or “JDC” means the committee established pursuant to
Article II of this Agreement.

     1.59 “Joint Initial Development Expenses” means Initial Development Expenses incurred by GTx [
* ] relating to the Initial Development of the Initial Products in the ADT Indication and the PIN
Indication; provided however, that (a) such Joint Initial Development Expenses shall only include
Initial Development Expenses incurred in connection with Initial Development activities which are
required for or conducted taking into consideration potential requirements for (i) the Initial
Development of Initial Products in the ADT Indication and the PIN Indication (subject to Ipsen’s
Election pursuant to Section 4.2(e)(i) of this Agreement) within the European Territory or (ii) the
obtaining of Regulatory Approvals for the Initial Products in the ADT Indication and the PIN
Indication (subject to Ipsen’s Election
pursuant to Section 4.2(e)(i) of this Agreement) in the European Territory or (iii) the
maintenance of Regulatory Approvals for the Initial Products in the ADT Indication and the PIN
Indication (subject to Ipsen’s Election pursuant to Section 4.2(e)(i) of this Agreement) in the
European Territory, and (b) such Joint Initial Development Expenses are included in the GTX Initial
Development Budget. Such Joint Initial Development Expenses shall include [ * ].

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 7.

 

     1.60 “Joint Invention” means any Invention made by the Parties in the course of the Initial
Development pursuant to Section 4.2(g) of this Agreement and/or a Joint Subsequent Development
pursuant to Section 4.3 (b)(v) of this Agreement.

     1.61 “Joint Patent” shall mean any Patent Covering a Joint Invention.

     1.62 “Joint PIN Initial Development Expenses” shall have the meaning set forth in Section
4.2(f)(iii) of this Agreement.

     1.63 “Joint Subsequent Development” shall have the meaning ascribed to it in Section 4.3(a) of
this Agreement.

     1.64 “Joint Subsequent Development Budget”, “Joint Subsequent Development Costs”, “Joint
Subsequent Development Plan” shall have the meaning ascribed to it in Section 4.3(b) of this
Agreement.

     1.65 “Launch Date” means the date of the first offer for commercial sale, following Regulatory
Approval of a Licensed Product within the European Territory. [ * ].

     1.66 “Licensed Product” means a drug product containing Toremifene as an Active Ingredient for
use in humans for all Indications, in a form suitable for sale to an end user, and/or for use in
conducting Pre-Clinical Studies and Clinical Studies. Licensed Product shall include, without
limitation, all doses of the Initial Products and any Product Improvement.

     1.67 “Licensed Trademark” means trademarks Controlled by GTx licensed hereunder to Ipsen
pertaining to the Initial Products and which are listed in Appendix B.

     1.68 “List Price” shall mean Ex-manufacturer IMS-MIDAS price list on a per milligram basis.

     1.69 “Major Country” means any of the following countries: the United Kingdom, France,
Germany, Spain and Italy.

     1.70 “Marketing and Sales Committee” shall have the meaning set forth in Section 6.2 of this
Agreement.

     1.71 “Marketing and Sales Plan” shall have the meaning set forth in Section 6.3 of this
Agreement.

     1.72 “Milestone Event” shall have the meaning set forth in Section 3.2 of this Agreement.

     1.73 “NDA” shall mean New Drug Application (as that term is used in Title 21 of the United
States Code of Federal Regulations) or any foreign equivalent filed with a Regulatory Agency to
market and sell any product for a particular indication.

     1.74 “Net Sales” means, consistent with, in the European Territory, Ipsen’s worldwide

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 8.

 

accounting policies and procedures, and in each such case as consistently applied across the Ipsen
pharmaceutical product line, the gross sales invoiced by Ipsen, its Affiliates, and sub-licensees
to Third Parties for Licensed Product in the European Territory, less:

          (a) credits and allowances or adjustments granted to customers on account of rejections,
recalls or returns of Licensed Product previously sold;

          (b) any customary and reasonable trade and cash discounts, rebates, including government
rebates, granted in connection with sale of Licensed Product to such customers;

          (c) sales, tariff duties and/or use taxes directly imposed and with reference to particular
sales; and

          (d) outbound transportation prepaid or allowed, amounts allowed or credited on returns, export
licenses, import duties, value added tax, and prepaid freight.

Sales of Licensed Product by and between Ipsen and its Affiliates, sublicensees are not sales to
Third Parties and shall be excluded from Net Sales calculations for all purposes. Sales of
Licensed Product for use in conducting clinical trials of Licensed Product candidates in a country
within the European Territory in order to obtain applicable Regulatory Approval of the Licensed
Product in the European Territory shall be excluded from Net Sales calculations for all purposes.

“Net Sales” of a Bundled Product. In the event Licensed Product is sold as part of a Bundled
Product in a country within the European Territory, the Net Sales of the Licensed Product, for the
purposes of determining payments based on Net Sales, shall be determined by multiplying the Net
Sales of the Bundled Product in such country, during the applicable Net Sales reporting period, by
the fraction, A/(A+B), where:

A is the average sale price of the Licensed Product by Ipsen (i.e. Net Sales divided by units
sold), its Affiliates or sublicensees when sold separately in finished form in such country and B
is the average sale price by Ipsen, its Affiliates or sublicensees of the other product(s) included
in the Bundled Product when sold separately in finished form in such country, in each case during
the applicable Net Sales reporting period.

In the event the Licensed Product is sold as part of a Bundled Product and is sold separately in
finished form in such country, but the other product(s) included in the Bundled Product are not
sold separately in finished form in such country, the Net Sales of the Licensed Product, for the
purposes of determining payments based on Net Sales, shall be determined by multiplying the Net
Sales of the Bundled Product in such country by the fraction C/D where:

C is the average sale price, in such country, of the Licensed Product contained in such Bundled
Product when sold separately and D is the average sale price, in such country, for the Bundled
Product, in each case during the applicable Net Sales reporting period.

In the event that the Licensed Product is not sold separately in finished form in the country, but
all of the other product(s) included in the Bundled Product in such country are sold separately,
the Net Sales of the Licensed Product, for the purposes of determining payments based on Net

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 9.

 

Sales,
shall be determined by multiplying the Net Sales of the Bundled Product in such country by the
fraction (D-E)/D, where:

D is the average sale price, in such country, of the Bundled Product, and E is the average sale
price of the other product(s) included in the Bundled Product in finished form in such country, in
each case during the applicable Net Sales reporting period.

In the event that the Net Sales of the Licensed Product when included in a Bundled Product cannot
be determined using the methods above, Net Sales for the purposes of determining payments based on
Net Sales shall be calculated by multiplying the Net Sales of the Bundled Product by the fraction
of F/(F+G) where:

F is the fair market value of the Licensed Product and G is the Fair Market Value of all other
pharmaceutical product(s) included in the Bundled Product, as reasonably determined in good faith
by the Parties. For the purposes of this Section 1.74, “Fair Market Value” shall mean the cash
consideration that a willing seller would realize from an unaffiliated, unrelated and willing buyer
in an arms’ length sale of an identical item sold in the same quantity and at the same time and
place of the transaction.

     1.75 “Opt-in” shall have the meaning set forth in Section 4.3(c)(i) of this Agreement.

     1.76 “Opt-in Information” shall have the meaning set forth in Section 4.3(c)(ii) of this
Agreement.

     1.77 “Opt-in Party”, “Opt-in Payment”, “Opt-in Period”, “Opt-in Period 1”, “Opt-in Period 2”,
“Opt-in Period 3”, “Opt-in Period 4”, “Opt-in Period 5”, “Opt-in Notification” , and “Opt-in
Payment” shall have the meaning set forth in Section 4.3(c)(iii) of this Agreement.

     1.78 “Opt-out Party” shall have the meaning set forth in Section 4.3(b)(iv) of this Agreement.

     1.79 “Non-Developing Party” shall have the meaning set forth in Section 4.3(c)(i) of this
Agreement.

     1.80 “Orion” shall have the meaning set forth in the Recitals.

     1.81 “Orion License” means the Amended and Restated License and Supply Agreement dated January
1, 2005 by and between GTx and Orion, as the same may be amended from time to time.

     1.82 “Past Initial Development Expenses” shall have the meaning ascribed to it in Section
4.2(e)(iii) of this Agreement.

     1.83 “Patent” means (a) United States patents, re-examinations, reissues, renewals, extensions
and term restorations, supplemental protection certificates, and foreign counterparts thereof, and
(b) pending applications for United States patents, including, without limitation,

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 10.

 

provisional
applications, continuations, continuations-in-part, divisional and substitute applications,
including, without limitation, inventors’ certificates, and (c) foreign counterparts of any of the
foregoing.

     1.84 “Patent Expenses” means the fees, expenses and disbursements of outside counsel, and
payments to Third Party agents, incurred in connection with the preparation, filing, prosecution
and maintenance of GTx Patents, Joint Patents or Ipsen Patents including the costs of Patent
interference and opposition proceedings but excluding the costs of any other Patent enforcement
proceedings.

     1.85 “Phase III Clinical Trial(s)” means that portion of the clinical development program
which provides for continued trials of a Licensed Product on sufficient numbers of patients to
establish the Safety and efficacy of a Licensed Product and generate pharmaco-economic data to
support Regulatory Approval in the proposed therapeutic indication, as more fully defined in 21
C.F.R. § 312.21(c).

     1.86 “Phase IIIB Clinical Trial(s)” means product support clinical trials of a Licensed
Product, which is not required for receipt of initial Regulatory Approval but which may be useful
in providing additional drug profile data or expansion of the Licensed Product’s label claim.
Phase IIIB Clinical Trials shall include GTx’s one year extension trial of an 80 mg dose of Initial
Products for the ADT Indication.

     1.87 “Phase IV Clinical Trial(s)” means product support clinical trials, including but not
limited to trials for new drug delivery systems, of a Licensed Product with an approved label claim
that is commenced after receipt of Regulatory Approval in the country where such trial is being
conducted.

     1.88 “PIN” means high grade prostatic intraepithelial neoplasia.

     1.89 “PIN Indication” means the prevention of prostate cancer in men with PIN.

     1.90 “PIN Trial” shall have the meaning set forth in the Recitals.

     1.91 “Pre-Clinical Studies” means studies of a Licensed Product in animals other than humans,
including those studies conducted in whole animals and other test systems, designed to determine
the pharmacology, toxicity, absorption, distribution, metabolism, excretion, and immunology of an
Active Ingredient.

     1.92 “Pre Opt-in Development Costs” shall have the meaning set forth in Section 4.3(c)(ii) of
this Agreement.

     1.93 “Pricing and Reimbursement Approval” means the pricing and reimbursement approval for the
Licensed Product from the Relevant Agency, as required.

     1.94 “Primary Endpoint” means each of the primary efficacy endpoints within the PIN Trial and
ADT Trial, respectively, as set forth in the respective SPA approved by the FDA for each such trial
and the protocol for each such trial encompassed within each such SPA.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 11.

 

Primary Endpoints for each
of the PIN Trial and ADT Trial are set forth in Exhibit C.

     1.95 “Product Improvement” shall mean [ * ].

     1.96 “Regulatory Agency” means any governmental authority, including without limitation the
FDA or EMEA and the European Commission, with responsibility for granting any licenses or
Regulatory Approvals or granting pricing and/or reimbursement approvals necessary for the marketing
and sale of a Licensed Product in any country or group of countries.

     1.97 “Regulatory Approval” means any approvals by a Regulatory Agency (with the exception of
conditional approvals) that are necessary for the commercial manufacture, use, storage,
importation, export, transport or sale of Licensed Products in a regulatory jurisdiction.

     1.98 “Royalty Payment” shall have the meaning set forth in Section 3.4 of this Agreement.

     1.99 “Royalty Reduction” and “Royalty Reduction Cap” shall have the meaning set forth in
Section 3.4 of this Agreement.

     1.100 “Royalty Term” shall have the meaning set forth in Section 3.8 of this Agreement.

     1.101 “Safety” means the absence of adverse experiences associated with the administration of
a drug to a patient that are significant, serious or life threatening to the patient or demonstrate
significant toxicological effect(s) of such drug on one or more body tissues that are not balanced
by a countervailing benefit to the patient. The Safety of a product will be determined in view of
the risk to benefit relationship of such product in the relevant patient population.

     1.102 “SERM” means selective estrogen receptor modulator other than Toremifene.

     1.103 “Sole Subsequent Development” shall have the meaning set forth in Section 4.3(a) of this
Agreement.

     1.104 “SPA” shall have the meaning set for in the Recitals.

     1.105 “Subsequent Development” shall have the meaning set forth in Section 4.3(a) of this
Agreement.

     1.106 “Supply Price” shall refer to the “PIN Supply Price” and the “ADT Supply Price”
described in Section 3.4 of this Agreement.

     1.107 “Tax” shall have the meaning set forth in Section 3.12(c) of this Agreement.

     1.108 “Third Party” means any entity other than GTx or Ipsen, or any of their respective
Affiliates.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 12.

 

     1.109 “Third Party License” have the meaning set forth in Section 4.3(b)(ii) of this
Agreement.

     1.110 “Toremifene” shall mean [ * ].

     1.111 “UTRF” shall have the meaning set forth in the Recitals.

     1.112 “UTRF License” means the Amended and Restated Exclusive License Agreement dated July 24,
1998, by and between GTx and UTRF (formerly known as the University of Tennessee Research
Corporation) exclusively licensing to GTx all UTRF know-how and Patents pertaining to methods of
using Toremifene for the PIN Indication, as the same may be amended from time to time

     1.113 “Valid Patent Claim” means an unexpired claim (a) of any issued Patent that has not been
revoked or held unenforceable or invalid by a decision of a court or governmental agency of
competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not
taken within the time allowed for appeal, and that has not been disclaimed or admitted to be
invalid or unenforceable through reissue, disclaimer or otherwise, or (b) of any patent application
that has not been cancelled, withdrawn or abandoned or been pending more than seven (7) years.

     1.114 “Withholding Royalty Payments” shall have the meaning set forth in Section 3.9 of this
Agreement.

ARTICLE II

JOINT DEVELOPMENT COMMITTEE

     2.1 Formation of JDC. Promptly after the Effective Date, GTx and Ipsen shall form a Joint
Development Committee (“JDC”) comprised of equal numbers of reasonably qualified representatives of
each Party (not to exceed three (3) representatives of each Party) who have expertise in the
clinical development, registration and commercialization of pharmaceutical products, with one such
person assigned by each Party as such Party’s co-chair (each, a “Co-Chair”). Either Party may
designate a substitute for a committee member to participate in the event one of that Party’s
regular committee members is unable to be present at a meeting. The
formation of the JDC as well as its responsibilities may be amended from time to time by
mutual agreement of the Parties.

     2.2 Meetings. Meetings of each of the JDC may be called by either Party on [ * ] written
notice to the other unless such notice is waived by the Parties. Such committees may be convened,
polled or consulted from time to time by means of telecommunication, video communication, or
correspondence. Notwithstanding the foregoing, the JDC will meet at least quarterly, with
face-to-face meetings being required at least twice a year at alternating sites to be designated by
GTx and Ipsen, and the other meetings being conducted face-to-face or through teleconference or
video conference, as agreed upon by the JDC. With the prior consent of the

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 13.

 

other Party’s Co-Chair
(such consent not to be unreasonably withheld or delayed), each Party may invite non-members to
participate in the discussions and meetings of the JDC, provided that such participants shall have
no vote and shall be subject to the confidentiality provisions set forth in Article IX.

     2.3 Agendas. Each Party will disclose to the other proposed agenda items for discussion,
along with appropriate related Information, at least [ * ] in advance of each meeting of the JDC.

     2.4 Responsibilities of the JDC.

          (a) The JDC will facilitate communications between the Parties regarding each of the Parties’
development of Licensed Products in each of their respective territories (e.g., GTx’s development
of Licensed Products in the GTx Territory, and Ipsen’s development of Licensed Products in the
European Territory).

          (b) Ipsen shall present to the JDC within [ * ] of the Effective Date the Ipsen Initial
Development Plan that relates to the Ipsen Initial Development in the European Territory through
2007 with such level of detail as is necessary and appropriate for all JDC members to fully
understand such Ipsen Initial Development Plan.

          (c) For each calendar year subsequent to 2007, a revised annual Initial Development Plan and
Initial Development Budget for GTx Initial Development in the GTx Territory and a revised Ipsen
Initial Development Plan in the European Territory will be prepared by the appropriate Parties and
submitted to the JDC before [ * ] of the calendar year proceeding the calendar year for which the
revised Initial Development Plans and the revised Initial Development Budget applies.

          (d) The JDC will review, discuss and comment on the Initial Development Plans and Initial
Development Budget. GTx and Ipsen will each update the JDC periodically, but at least quarterly,
of all of their respective material Initial Development activities.

          (e) The JDC will review, comment on, and provide recommendations on any Subsequent Development
of Product Improvements under the terms set forth in Section 4.3.

          (f) All recommendations by the JDC that relate to either GTx Initial Development or Ipsen
Initial Development shall be made [ * ], after an open and informed discussion of the matters as
to which decisions are being made, including, but not limited to those matters relating to each
such Initial Development Plan and Initial Development Budget. If the JDC is unable to make a [ *
] decision on such matters, the matter will be referred to the Executive Officers of GTx and Ipsen.
If such officers do not reach agreement on such matter within [ * ] after it is referred to
them, then the decision of [ * ] on matters pertaining to [ * ] (except those related to (i)
Initial Development activities conducted by [ * ] which are supportive of the [ * ] and (ii)
Joint Initial Development Expenses related thereto) and the decision of [ * ] on matters
pertaining to [ * ] will be final and determinative, so long as such

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 14.

 

decision does not contradict
or modify the terms of this Agreement. Notwithstanding the preceding sentence, (i) any decision
relating to Joint Initial Development Expenses shall require the mutual consent of both Parties and
(ii) both Parties agree that before they undertake any Initial Development activities that can
materially affect the Initial Development activities of the other Party (including, in particular,
Initial Development activities conducted by GTx which are supportive of the Initial Development
activities of Ipsen for the European Territory), the Party desiring to conduct such Initial
Development activities shall take into account any reasonable suggestion of the other Party. In the
event the Parties (through the JDC, or, their Executive Officers) do not reach agreement on matters
relating to [ * ], Ipsen shall have the right not to fund its share of such Joint Initial
Development Expenses which GTx shall have the right to undertake. In the event that Ipsen later
decides that it wishes to have access to and use the data from such Initial Development activities
that Ipsen refused to fund pursuant to its right above, Ipsen shall reimburse GTx [ * ] of
Initial Development Expenses pertaining to such Initial Development activities.

     2.5 Subcommittees of the JDC. The JDC will have the power to form subcommittees with equal
(unless otherwise agreed in writing) and appropriate representation from GTx and Ipsen.

ARTICLE III

LICENSING FEES; MILESTONE PAYMENTS; ROYALTIES; REPORTING

     3.1 License Fee, Initial Development Expenses, and Election Fee.

          (a) License Fee. As partial consideration for the rights granted by GTx pursuant to this
Agreement, Ipsen shall pay to GTx a non-refundable, non-creditable license fee of [ * ] (the
“License Fee”) as follows: (i) [ * ] of such License Fee shall be paid to GTx within [ * ]
after the Effective Date of this Agreement; and (ii) the remaining 1.5 Million Euro amount of the
License Fee shall be paid in three (3) equal installments of 500,000 Euros each on the 1st, 2nd and
3rd anniversary dates of the Effective Date of the Agreement.

          (b) Initial Products Development Expenses Reimbursement. Within [ * ] after the Effective
Date, Ipsen shall pay to GTx a non-refundable, non-creditable fee of [ * ] as reimbursement for
Initial Development Expenses incurred by GTx in connection with Pre-
Clinical Studies and Clinical Studies for the Initial Products that were initiated, conducted,
or ongoing prior to the Effective Date.

          (c) Election Fee. In the event that Ipsen exercises its Election (as defined in Section
4.2(e)(i) of this Agreement), Ipsen shall pay to GTx an additional fee of [ * ] (the “Election
Fee”) within [ * ] following notice of exercise of such Election to GTx; provided, however, that
such Election Fee shall not be due in the event that Ipsen exercises its Election during the
Initial Election Period, as provided in Section 4.2(e)(iii).

     3.2 Milestone Payments. In addition to the payments due to GTx under Section 3.1, and in
consideration for the rights granted by GTx pursuant to this Agreement, Ipsen shall make

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 15.

 

 the
following non-refundable, non-creditable (except as expressly provided for in the payments
described in Milestone Events 5 and 6 below) milestone payments to GTx after the occurrence of each
event that follows (each, a “Milestone Event”). The payments set forth herein shall each be due and
payable by Ipsen within [ * ] following receipt from GTx of a notice and invoice regarding the
achievement of each Milestone Event set forth herein.

	 	 	 
	Milestone Event	 	Payment (in Euros)
	1. Achievement of [ * ]

	 	[ * ]
	 
	 	 
	2. Achievement of [ * ]1 

	 	[ * ]
	 
	 	 
	3. Filing with the EMEA or with the relevant
Regulatory Agency [ * ] for Regulatory
Approval of [ * ]1

	 	[ * ]
	 
	 	 
	4. Filing with the EMEA or with the relevant
Regulatory Agency [ * ] for Regulatory
Approval of [ * ]

	 	[ * ]
	 
	 	 
	5. Obtaining a Regulatory Approval by the
EMEA/European Commission or by the Regulatory
Agency [ * ] of [ * ]1,2

	 	[ * ]4
	 
	 	 
	6. Obtaining a Regulatory Approval by the
EMEA/European Commission or by the Regulatory
Agency [ * ] of [ * ]3

	 	[ * ]5
	 
	 	 
	7. On a [ * ] basis, the determination by
the relevant Regulatory Agency of a List
Price for [ * ]1

	 	[ * ]6
	 
	 	 
	8. Obtaining a Regulatory Approval [ * ]
for a diagnostic test for [ * ]1

	 	[ * ]

 

			
	1	 	In the event Ipsen has not made the Election pursuant to Section 4.2(e)(i) of this
Agreement at
the time any of such Milestone Events (either Milestone Event numbers 2, 3, 5, 7 or 8) are
achieved, then the payment associated with each such Milestone Event shall be deferred until no
later than thirty (30) calendar days after Ipsen shall have make such Election, at which time all
such deferred milestone payments shall become promptly due and payable to GTx.
	 
	2	 	[ * ].
	 
	3	 	[ * ].
	 
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 16.

 

			
	4	 	This total milestone payment shall be allocated among the various Major Countries based
on the estimated relative market sizes for the PIN Indication, as follows: the United Kingdom: [ *
]; France: [ * ]; Germany: [ * ]; Italy [ * ]; and Spain: [ * ].
	 
	5	 	This total milestone payment shall be allocated among the various Major Countries based
on the estimated relative market sizes for the ADT Indication, as follows: the United Kingdom: [ *
]; France: [ * ]; Germany: [ * ]; Italy [ * ]; and Spain: [ * ].
	 
	6	 	This total milestone payment shall be allocated among the various Major Countries based
on the estimated relative market sizes, as follows: the United Kingdom: [ * ]; France: [ * ];
Germany: [ * ]; Italy [ * ]; and Spain: [ * ].

     3.3 Limitation on Milestone Payments. Other than the milestone payments recited in Section
3.2, Ipsen shall not be obligated to make any other milestone payments in connection with Initial
Products or any other Licensed Product.

     3.4 Royalty Payments.

          (a) In consideration for the rights granted to Ipsen under this Agreement, Ipsen shall pay to
GTx quarterly royalty payments on Net Sales determined as follows (the “Royalty Payment”) :

               (i) For the first calendar year as from the first Launch Date of the Licensed Product in the
European Territory (“Y1”), Ipsen shall pay, on a country-by-country basis a Royalty Payment equal
to the applicable royalty rates set forth in this Section 3.4(a)(i) (the “Base Royalty Rate”),
multiplied by the Net Sales of Licensed Product for the PIN and ADT Indications (respectively the
“PIN Base Royalty rate” and the “ADT Base Royalty Rate”) .

                    (A) the PIN Base Royalty shall be equal to the greater of [ * ] and F, where F is the
result of the following calculation:

[ * ].

                    (B) the ADT Base Royalty shall be equal to the greater of [ * ] and G, where G is the
result of the following calculation:

[ * ].

For the purposes of calculating Expected Price for the PIN and ADT Indications for the initial
calculation of the PIN and ADT Base Royalty, Ipsen shall update its forecast based upon the actual
prices received from the appropriate agency upon receiving Pricing and Reimbursement Approval for
products that have launched in the first quarter when the Royalty Payment is due.

               (ii) Within [ * ] as from the end of the Y1, Ipsen shall determine the following amounts :

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 17.

 

	 	•	 	“A” which is equal to the aggregate annual Net Sales of the Licensed Product of Y1
multiplied by the following royalty rates:

	 	 	 
	[ * ]

	 	[ * ]
	 
	 	 
	[ * ]

	 	[ * ]
	 
	 	 
	[ * ]

	 	[ * ]
	 
	 	 
	[ * ]

	 	[ * ]

	 	•	 	“B” which is equal to [ * ]
	 
	 	•	 	“PIN Supply Price” being equal to [ * ].
	 
	 	•	 	“C” which is equal to [ * ]. For clarity, [ * ].

                    (A) In the event B is superior to C, then:

                         (i) [ * ];

                         (ii) [ * ].

                    (B) In the event B is inferior to C, then:

                         (i) [ * ].

                         (ii) [ * ].

                         For the following calendar years (“Y”) (notwithstanding the Offset set forth above):

                         (A) [ * ];

                         (B) [ * ];

                         (C) [ * ];

                         (D) [ * ];

                         (E) [ * ].

                         Examples Rates are attached hereto as Exhibit D for purposes of further clarification for the
calculations described in this Section 3.4.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 18.

 

          (b) Generic Competition. If a Generic is sold in any Major Country of the European Territory
and for two (2) succeeding calendar quarters the sales of such Generic in that country equal or
exceed [ * ] of the Net Sales of Licensed Products (calculated on a unit basis) in that country
by Ipsen, its Affiliates or sublicensees, then the Royalty Payments shall be reduced to [ * ] of
the amount of the Royalty Payment otherwise due to GTx on account of Net Sales of such Licensed
Product for the ADT Indication or [ * ] of the amount of the Royalty Payment otherwise due to GTx
on account of Net Sales of such Licensed Product for the PIN Indication in such country with such
reduction to be applicable to the immediately succeeding calendar quarters only.

          (c) Dominating Patents. If (i) Ipsen would be prevented from developing, using, selling, or
importing the Licensed Products in any country of the European Territory on the grounds that by
doing so they would infringe one (or more) Dominating Patent held by a Third Party in said country
and (ii) Ipsen licenses rights to such Dominating Patent in said country, then [ * ] of any
royalties on Licensed Products sales paid by Ipsen to such Third Party in any calendar year in such
country with respect to such Dominating Patent shall be deducted from any Royalty Payments payable
to GTx by Ipsen in such calendar year (the “Royalty Reduction”), provided, however,
that (i) such Dominating Patent relates solely to [ * ] and (ii) GTx has been informed of the
Dominating Patent and has had an opportunity to provide input on any related discussion of whether
to license such Dominating Patent and negotiation of royalty rates; and (iii) subject to the
warranties and representations made by GTx under Section 10.1 (b) of this Agreement, the amount of
the Royalty Reduction in any calendar year shall not exceed [ * ] of the Royalty Payments (the
“Royalty Reduction Cap”) that would have otherwise been payable by Ipsen to GTx for such calendar
year and for such country. Any amount of the Royalty Reduction which is not offset against Royalty
Payments due to GTx from Ipsen (because it exceeds the Royalty Reduction Cap) shall be carried
forward to and deducted in subsequent calendar years until the expiration of the Royalty Term.

     3.5 Sales by Sublicensees. In the event Ipsen, subject to the provisions of this Agreement,
grants licenses or sublicenses to others to market and/or sell Licensed Product, including Initial
Products, such licenses or sublicenses shall include an obligation for the licensee or the
sublicensee to account for and report its Net Sales of Licensed Product on the same basis as if
such sales were Net Sales by Ipsen, and Ipsen shall pay royalties to GTx as if such sales by such
sublicensees were the Net Sales of Ipsen, subject to the provisions of this Article III.

     3.6 Relief From Certain Marketing Obligations. Notwithstanding anything to the contrary
herein, in the event that Ipsen’s COGS of a particular Licensed Product for a particular country
exceeds [ * ] of the Net Sales of such Licensed Product in such country:

          (a) Ipsen shall promptly provide notice to GTx of its belief that the COGS of a particular
Licensed Product has exceeded or will exceed [ * ] of Net Sales in such country. Ipsen shall
include with any such notice a calculation of such percentage and appropriate documentation and
records supporting its calculation of COGS and Net Sales of such Licensed Product in such country.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 19.

 

          (b) The Parties will have [ * ] following GTx’s receipt of such notice to discuss in good
faith whether an adjustment of the Royalty Payments under Section 3.4 of this Agreement is
appropriate so that COGS for such Licensed Product do not exceed [ * ] of Net Sales of such
Licensed Product in such country or whether other circumstances exist that may warrant Ipsen
continuing to sell such Licensed Product in the country in question. In the event the Parties fail
to reach an agreement on any such adjustment, Ipsen shall not have to commercialize the Licensed
Products in such country as long as Ipsen reasonably believes circumstances have not sufficiently
changed to allow it to have COGS [ * ].

     3.7 Payment of Royalties; Reporting. Within [ * ] after the end of each calendar quarter
for which Royalty Payments are payable by Ipsen to GTx with respect to Net Sales by Ipsen, its
Affiliates and their respective sublicensees, Ipsen shall pay to GTx by wire transfer the Royalty
Payment due for such quarter and submit to GTx a report, on a country by country basis, providing
in reasonable detail an accounting of all Net Sales (including an accounting of all unit sales of
Initial Products on a per dose and per Indication basis) made during such calendar quarter, and the
calculation prepared by Ipsen to determine the applicable Royalty Payment due for such quarter
pursuant to this Article III. Within [ * ] after the end of each calendar year for which Royalty
Payments are payable by Ipsen to GTx, Ipsen shall provide to GTx a report, on a country by country
basis, reconciling the number of Initial Products sold on a per dose and a per Indication basis to
the number of Initial Products consumed per Indication. In the event any payment due to GTx,
including the Royalty Payments due hereunder, are late by more than [ * ], GTx shall have the
right to assess interest on the amounts which are then past due and owing to GTx at a rate of
interest equal to the prime rate [ * ].

     3.8 Royalty Term. Royalties shall be payable [ * ] (hereinafter, the “Royalty Term”). In
the event that: (i) a Product Improvement is either jointly developed pursuant to Section 4.3(b) of
this Agreement or developed by Ipsen and GTx has opted-in pursuant to Section 4.3(c), (ii) such
Product Improvement is covered by an Ipsen Patent or a Joint Patent and (iii) such Product
Improvement is commercialized in the European Territory by Ipsen, then, with regards to such
Product Improvement, the Royalty Term shall [ * ].

     3.9 [ * ].

     3.10 Ipsen’s Rights Upon Expiration of Royalty Term. Upon expiration of the Royalty Term for
a Licensed Product on a country-by-country basis as described above, Ipsen shall thereafter have a
paid-up, non-exclusive license under the GTx Patents and GTx Know-how to use, sell, offer for sale,
have sold and import that Licensed Product in that country.

     3.11 Tax Matters.

          (a) Ipsen Payments to GTx of Withholding Tax. If provision is made in law or regulation of any
country in the European Territory for withholding of Taxes with respect to any amounts payable by
Ipsen to GTx pursuant to this Agreement, Ipsen shall promptly pay such Tax on behalf of GTx to the
proper governmental authority and Ipsen shall promptly furnish GTx with certificate of Taxes
deducted under such withholding tax laws. Ipsen shall have the right to offset any such Tax
actually paid from any payment due to GTx or shall be

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 20.

 

promptly reimbursed by GTx if no further
payments are due. GTx and Ipsen shall cooperate with each other in obtaining any exemption from or
reduced rate of Tax available under any applicable law or tax treaty.

          (b) Income and Other Taxes of the Parties. Ipsen and GTx shall pay for their own account all
sales, turnover, income, revenue, value added and other taxes levied on account of payments
accruing or made under this Agreement. All amounts expressed in this Agreement exclude such taxes
where required by law

          (c) Tax. Solely for purposes of this Section 3.11, “Tax” or “Taxes” means any present or
future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including
interest, penalties and additions thereto) that are imposed by a government taxing authority on
GTx’s receipt of payments hereunder. Notwithstanding the foregoing, “Tax” or “Taxes” shall not
include charges, value-added taxes, taxes imposed on Ipsen’s income, or assessments or fees of any
nature (or any interest, penalties or additions thereto) imposed by the FDA or any Regulatory
Agencies.

          (d) Protest. Ipsen shall promptly notify GTx in writing of any assessment, proposed
assessment or other claim for any additional amount of Tax assessed by the US. Notwithstanding any
other provision of this Section 3.11, GTx may, at its own expense, protest any assessment, proposed
assessment, or other claim by any governmental authority for any additional amount of Tax or seek a
refund of such amounts paid if permitted to do so by law or if the payment of such amounts are its
ultimate contractual responsibility under the terms of this Agreement. Ipsen shall cooperate with
GTx in any protest by providing records, giving testimony and providing such additional information
or assistance as may reasonably be necessary to pursue such protest.

     3.12 Currency. Except as specified in the last sentence of this Section, all amounts
specified in this Agreement which are to be paid to GTx are to be in Euros, as set forth in Section
15.16 of this Agreement. When calculating Net Sales for Royalty Payments, Ipsen shall convert the
amount of invoiced sales in currencies other than Euros into Euros using the exchange rates [ *
]. All payments related to the development costs will be made in the currency of the invoicing
party.

     3.13 Payments to or Reports by Affiliates. Any payment required under any provision of this
Agreement to be made to GTx, or any report required to be made by Ipsen, shall be made to or by an
Affiliate of such Party if such Affiliate is designated by that Party as the appropriate recipient
or reporting entity.

     3.14 Payments by Wire Transfer. Any payments due to GTx hereunder shall be made by wire
transfer to the following (or as provided in any alternative instructions that GTx may provide by
written notice to Ipsen from time to time): [ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 21.

 

ARTICLE IV

DEVELOPMENT AND REGISTRATION

     4.1 Development Responsibilities. As a general principle, GTx will be solely responsible for
the development of Licensed Products in the GTx Territory and for any communication with Regulatory
Agencies in the GTx Territory, and Ipsen will be solely responsible for the development of Licensed
Products in the European Territory and for any communication with Regulatory Agencies in the
European Territory. Neither Party will undertake to conduct any development activities for Licensed
Products in the territory of the other Party without first submitting the proposed development
activities to the JDC and receiving the approval of the other Party which shall not be unreasonably
withheld or delayed.

4.2 Initial Development.

          (a) Initial Development Plan.

               (i) GTx Initial Development. The Initial Development of the Initial Products for the ADT
Indication and the PIN Indication in the GTx Territory shall be carried out by GTx pursuant to a
development plan (the “GTx Initial Development Plan”) and a development budget (the “GTx Initial
Development Budget”), both of which are attached as Exhibit E of this Agreement. The GTx Initial
Development Budget comprises the Initial Development Expenses incurred by GTx as from [ * ]
through [ * ] and the forecasted Initial Development Expenses as from [ * ] and until the
obtaining of the Regulatory Approval for the Initial Products in the GTx Territory, differentiated
between (i) Initial Development Expenses incurred/forecasted for the Development of the ADT
Indication and the Initial Development of the PIN Indication and (ii) Joint Initial Development
Expenses and other Initial Development Expenses. In the event that there are Joint Initial
Development Expenses that are not clearly dedicated to the Initial Development of either ADT
Indication or PIN Indication, the sum of such Joint Initial Development Expenses shall be allocated
equally as the Initial Development of ADT Indication and PIN Indication. For each calendar year
subsequent to 2006, a revised GTx Initial Development Plan and a revised GTx Initial Development
Budget will be prepared by GTx and submitted for approval to the JDC before [ * ] of each
calendar year, provided, however that any revision of the GTx Initial Development Plan and GTx
Initial Development Budget shall not result in an increase of [ * ] of Joint Development Expenses
per year, except as otherwise agreed by Ipsen.

               (ii) Ipsen Initial Development. The Initial Development of the Initial Products for the
obtaining of the ADT Indication and the PIN Indication in the European Territory shall be carried
out by Ipsen pursuant to a development plan for the remainder of 2006 and 2007 (the “Ipsen Initial
Development Plan”). The Ipsen Initial Development Plan will be submitted by Ipsen to the JDC within
[ * ] as from the Effective Date. For each calendar year
subsequent to 2007, a revised Ipsen Initial Development Plan will be prepared by Ipsen and
submitted for information to the JDC before [ * ] of each calendar year.

          (b) Content of Initial Development Plan. Each Initial Development Plan

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 22.

 

shall describe the
proposed overall program of all the Initial Development of a Party in its respective territory,
including, but not limited to, Pre-Clinical Studies, toxicology, formulation, chemical process
development, Clinical Studies, regulatory plans and other elements of obtaining Regulatory
Approval, and projected timelines for the Initial Development events. Each Initial Development
Plan for either GTx Initial Development or Ipsen Initial Development will identify endpoints needed
for initiation of the next phase of the Initial Development. Both GTx Initial Development Plan and
Ipsen Initial Development Plan will be submitted for comments by GTx to Orion and GTx shall inform
Ipsen of all comments made by Orion on the Initial Development Plans. Ipsen agrees to change and/or
amend the Ipsen Initial Development Plan to the extent such Ipsen Initial Development Plan could
reasonably be deemed to affect adversely Orion’s development, commercialization, sales or
registration of Fareston by Orion.

          (c) Initial Development Efforts. In carrying out Initial Development and its Initial
Development Plan in its respective territory, each Party agrees to use commercially reasonable
efforts to conduct the Initial Development of the Initial Products in the ADT Indication and the
PIN Indication and to conduct the activities set forth in their respective Initial Development Plan
in accordance with the timelines set forth therein. A Party’s material failure to comply with such
diligence obligations shall constitute a breach of this Agreement.

          (d) Drug Approval Applications. Consistent with its Initial Development Plan, GTx shall be
responsible for the filing of all Drug Approval Applications and seeking Regulatory Approvals for
Initial Products in the GTx Territory in the ADT Indication and the PIN Indication, and Ipsen shall
be responsible for the filing of Drug Approval Applications and seeking Regulatory Approvals for
Initial Products in the European Territory in the ADT Indication and the PIN Indication. If Ipsen
does not exercise the Election as set forth in Section 4.2(e) of this Agreement, GTx shall have the
right to seek Regulatory Approvals for Licensed Products for the PIN Indication in the European
Territory, provided, however, that GTx shall seek such Regulatory Approval under a trademark which
is not confusingly similar to the Licensed Trademarks to be used for the commercialization of the
Initial Products in the ADT Indication in the European Territory. The Parties shall consult and
cooperate in the preparation of each such Drug Approval Application and in obtaining Regulatory
Approvals. GTx shall solely own all Drug Approval Applications and Regulatory Approvals for the
GTx Territory and Ipsen shall solely own all Drug Approval Applications and Regulatory Approvals
for the European Territory. In the event that Ipsen does not exercise its Election, GTx shall
solely own all Drug Approval Applications and Regulatory Approvals for Licensed Products for the
PIN Indication in the European Territory.

          (e) Ipsen’s Election to Retain License Rights to Licensed Products for the PIN Indication.

               (i) Exercise of Election. Ipsen shall have the option, at its sole discretion, to
retain its license rights under Article V in connection with Licensed Products for
the PIN Indication, by notifying such election to GTx at any time after the Effective Date and
until [ * ] following receipt of the first Regulatory Approval in [ * ] (the “Election”).

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 23.

 

               (ii) Failure to Exercise Election. In the event Ipsen does not make the Election
within the period set forth in Section 4.2(e)(i) above or fails to make the payments required under
Section 4.2(e)(iii) below, then GTx shall have the right to terminate Ipsen’s license and
associated rights to Licensed Products for the PIN Indication, and thereafter GTx shall have the
exclusive right to commercialize the Licensed Product in the European Territory for the PIN
Indication, provided however that such commercialization shall be made under a trademark which
shall not be confusingly similar to the Licensed Trademarks to be used for the commercialization of
the Initial Products in the ADT Indication. Upon termination of such rights:

                    (1) Ipsen shall grant to GTx an exclusive, royalty-free license under any Ipsen Inventions
which would directly result from the conduct of the Ipsen Initial Development activities for the
PIN Indication to Develop, use, sell, have sold, offer for sale, import, export, and distribute the
Licensed Product for the PIN Indication in the European Territory;

                    (2) Within [ * ] of such termination, Ipsen shall transfer to GTx all data from Preclinical
Studies and Clinical Studies and other related Information as Ipsen may then Control pertaining to
such Licensed Product for the treatment of the PIN Indication, including any IND or similar
Regulatory Agency documents Ipsen may then Control for the purposes of conducting Clinical Studies
within the European Territory for the PIN Indication;

                    (3) Ipsen shall use commercial reasonable efforts to transfer to GTx all Regulatory Approvals
relating to the Licensed Product in the PIN Indication obtained in the European Territory; and

                    (4) Ipsen shall cease all on-going Initial Development of the Licensed Product in the PIN
Indication in the European Territory and shall not be obligated to make any payment pursuant to
Section 4.2(e)(iii) below.

               (iii) Election Fee and Payment of Past Initial Development Expenses. In the event Ipsen makes
such Election, Joint PIN Indication Development Expenses (as defined in Section 4.2(f)(iii)(2) of
this Agreement) shall be considered part of Joint Initial Development Expenses, and Ipsen will be
required to make the following payments : (i) within [ * ] as from the date of Election, the
Election Fee (as provided for in the chart below), (ii) within [ * ] as from the date of
Election, the reimbursement of the Joint PIN Initial Development Expenses which shall have accrued
from the date at which the aggregate Joint Initial Development Expenses (now inclusive of Joint PIN
Initial Development Expenses) incurred by GTx exceeded [ * ] in the aggregate and until the date
of Election (such costs during such period, the “Past Initial Development Expenses”) with a premium
as shown in the chart below and (iii) the payment of the Joint PIN Development Expenses as provided
for in Section 4.2(f)(iii)(2) of this Agreement.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 24.

 

	 	 	 	 	 	 	 
	Adjusted Payments with Premium for PIN Initial Development Expenses
	 	 	Premium on IPSEN	 	IPSEN share of Past	 	 
	 	 	share of Past	 	Initial	 	 
	 	 	Initial Development	 	Development	 	 
	Election Date	 	Expenses	 	Expenses	 	Election Fee
	A. Prior to the
expiry of a [ * ]
period as from
Effective Date( the
“Initial Election
Period”)

	 	[ * ]
	 	[ * ]
	 	[ * ]
	 
	 	 	 	 	 	 
	B. Between the date
of expiry of the
Initial Election
Period and receipt
by Ipsen of interim
data from Phase
III trial G300104
(IND [ * ])

	 	[ * ]
	 	[ * ]
	 	[ * ]
	 
	 	 	 	 	 	 
	C. Between receipt
by Ipsen of
G300104 Phase III
interim data and
receipt by Ipsen of
G300104 (IND [ *
]) final data

	 	[ * ]
	 	[ * ]
	 	[ * ]
	 
	 	 	 	 	 	 
	D. Between receipt
by IPSEN of G300104
(IND [ * ]) final
data and 90 days
after receipt by
IPSEN of G300104
(IND [ * ]) final
data, and in any
case, prior to
obtaining
Regulatory Approval
in European
Territory or in any
Major Country for
PIN Indication

	 	[ * ]
	 	[ * ]
	 	[ * ]
	 
	 	 	 	 	 	 
	E. Between 90 days
after receipt by
IPSEN of G300104
(IND [ * ]) final
data and [ * ]
after obtaining of
Regulatory Approval
in European
Territory or in any
Major Country for
PIN Indication

	 	[ * ]
	 	[ * ]
	 	[ * ]

By way of example only, in the event that GTx has expended more than [ * ] in Joint Initial
Development Expenses, and Ipsen exercises its Election after the expiration of the Initial Election
Period but before Ipsen’s receipt of G300104 (IND [ * ]) final data, it shall owe a payment to
GTx that is the sum of [ * ] of Past Initial Development Expenses, as well as an Election Fee of
[ * ].

          (f) Initial Development Expenses.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 25.

 

               (i) Initial Development Expenses Solely Borne by Ipsen. Ipsen shall be solely responsible for
paying all Initial Development Expenses that are not Joint Initial Development Expenses relating to
the obtaining of Regulatory Approvals in the European Territory for the Initial Products for the
ADT Indication and the PIN Indication (subject to the provisions of Section 4.2(e)(ii) of this
Agreement), which shall include the costs for any additional Pre-Clinical Studies and Clinical
Studies required exclusively by the EMEA or other Regulatory Agencies to grant Regulatory Approvals
for Initial Products within the European Territory.

               (ii) Initial Development Expenses Solely Borne by GTx. GTx shall be solely responsible for
paying all Initial Development Expenses that are not Joint Initial Development Expenses relating to
the obtaining of Regulatory Approvals for the Initial Products in the GTx Territory, including the
Initial Products for the ADT Indication and the PIN Indication (subject to the provisions of
Section 4.2(e)(ii) of this Agreement ), which shall include the costs for any additional
Pre-Clinical Studies and Clinical Studies required exclusively by the FDA or other Regulatory
Agencies to grant Regulatory Approvals for the Initial Products within the GTx Territory.

               (iii) Joint Initial Development Expenses. GTx shall bear the [ * ] of Joint Initial
Development Expenses. Thereafter, Joint Initial Development Expenses shall be allocated between
GTx and Ipsen as follows: [ * ] of Joint Initial Development Expenses shall be paid by GTx, and [
* ] of Joint Initial Development Expenses shall be paid by Ipsen as set forth below.

                    (1) Joint Initial Development Expenses for the Initial Products in the ADT Indication. At such
time as Joint Initial Development Expenses incurred by GTx exceed [ * ], GTx shall invoice Ipsen
on a quarterly basis for [ * ] of the Joint Initial Development Expenses relating to the Initial
Development of the Initial Products for the treatment of the ADT Indication (such Initial
Development Expenses referred to as the “Joint ADT Initial Development Expenses”). Ipsen shall
reimburse GTx for such costs within [ * ] of its receipt of such invoice.

                    (2) Joint Initial Development Expenses for Initial Products in the PIN Indication. Ipsen
shall not be responsible for paying any Joint Initial Development Expenses incurred in relation to
the Initial Development of the Initial Products for the treatment of the PIN Indication (“Joint PIN
Initial Development Expenses”), unless and until such time as Ipsen exercises its Election as set
forth in Section 4.2(e)(i). As from the Election and at such time as Joint Initial Development
Expenses (including Joint PIN Initial Development Expenses) incurred by GTx exceed [ * ], GTx
shall invoice Ipsen on a quarterly basis for [ * ] of the on-going Joint PIN Initial Development
Expenses and Ipsen shall reimburse GTx for such costs within [ * ] of its receipt of such
invoice.

                    (3) Reports and Adjustment. Within [ * ] after the end of each calendar quarter, GTx shall
provide Ipsen with a report detailing all GTx FTEs actually utilized by GTx during such calendar
quarter (by names and major tasks) and external costs (for which invoices were received and
approved for payment by GTx), as well as a comparison of

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 26.

 

such expenditures with the relevant provisions of the GTx Initial Development Budget. Within [
* ] of the end of 2006, and each calendar year thereafter, GTx shall provide to Ipsen an
accounting report of the actual Joint Initial Development Expenses incurred during the previous
calendar year including without limitation all detailed GTx FTE Costs as well as all invoiced
external costs. In the event Ipsen has overpaid or underpaid any amount in excess of its [ * ]
share in the Joint Initial Development Expenses as set forth in this report, GTx and Ipsen agree to
reimburse one another such amounts as are appropriate within [ * ] from the date of receipt by
Ipsen of this report. GTx agrees to maintain appropriate and accurate records of all Joint Initial
Development Expenses incurred by it.

                    (iv) Audits. Upon the written request of Ipsen (which shall be no more than [ * ]), GTx and
Ipsen shall agree on a mutually acceptable date on which to permit an independent certified public
accounting firm of an internationally recognized standing [ * ] to have access during normal
business hours to such of the records of GTx as may be reasonably necessary to verify the accuracy
of the reports and to audit the records as provided for in Section 4.2(f)(iii) of this Agreement.
The accounting firm shall disclose to GTx and Ipsen whether the reports/records are correct or
incorrect, the specific details concerning any discrepancies and such other information that should
properly be contained in an accounting report required under this Section. If such accounting firm
concludes that additional amounts relating to Ipsen’s share in Joint Initial Development Expenses
were owed, Ipsen shall pay such additional amounts within [ * ] of the date Ipsen delivers to GTx
such accounting firm’s written report so concluding. In the event such accounting firm concludes
that amounts relating to Ipsen’s share in Joint Initial Development Expenses were overpaid by
Ipsen, GTx shall repay Ipsen the amount of such overpayment within [ * ] of the date Ipsen
delivers to GTx such accounting firm’s written report so concluding. The fees charged by such
accounting firm shall be paid by Ipsen; provided, however, if the audit reveals
that Ipsen has overpaid by more than [ * ] Ipsen’s share of Joint Initial Development Expenses
due hereunder for the period being reviewed, then the fees and expenses of the accounting firm for
the audit shall be paid by GTx. Upon the expiry of [ * ] following the end of any calendar year
for which Ipsen has made payment of Joint Development Expenses with respect to such calendar year,
and in the absence of gross negligence or willful misconduct of GTx or a contrary finding by an
accounting firm pursuant to this Section, such calculation shall be binding and conclusive upon the
Parties, and GTx shall be released from any liability or accountability with respect to any over
payment by Ipsen for Joint Development Expenses for such calendar year.

          (g) Inventions under the Initial Development and license grant.

               In the event any Party makes an Invention during the course of the conduct of the Initial
Development, any such Invention shall be considered as a “Joint Invention”.

               Ipsen shall grant GTx an exclusive, royalty-free license on Ipsen’s interest in such Joint
Invention to develop, use, sell, have sold, offer for sale, import, export and distribute the
Initial Product in the GTx Territory.

     4.3 Subsequent Development.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 27.

 

          (a) Subsequent Development Proposals.

               Each Party acknowledges that no development of a GTx Product Improvement or an Ipsen Product
Improvement shall be made without first having been proposed to the other Party in accordance with
the provisions of this Section 4.3.

               The Party (the “Proposing Party”) intending to conduct the development of respectively an
Ipsen Product Improvement or a GTx Product Improvement (the “Subsequent Development”) shall notify
the JDC of such intent and shall provide to JDC all necessary information relating to the concerned
Product Improvement and the related Subsequent Development in order to enable the other Party to
reasonably assess the scientific, technical and commercial implications of the proposed Subsequent
Development. Within [ * ] from receipt of all such information, the other Party shall notify the
Proposing Party its decision or not to participate in the Subsequent Development.

               In the event the other Party decides not to participate in the Subsequent Development, the
Proposing Party shall be free to conduct the Subsequent Development at its own cost and expenses
(the “Sole Subsequent Development”) subject to the other Party’s right to decide at a later stage
to opt-in in such Subsequent Development in accordance to Section 4.3(c).

               In the event the other Party decides to participate to the Subsequent Development, the Parties
shall jointly perform and fund such Subsequent Development (the “Joint Subsequent Development”) as
set forth in Section 4.3(b) of this Agreement.

          (b) Joint Subsequent Development

               (i) Joint Subsequent Development Plan and Budget.

                    Following the other Party’s notification to join in the Subsequent Development, the Parties
working through the JDC shall agree upon a plan and a budget for the conduct of the Joint
Subsequent Development (respectively, the “Joint Subsequent Development Plan” and the “Joint
Subsequent Development Budget”) which shall include at least the following items:

               (A) research and development activities to be performed by each Party for the purpose of
obtaining Regulatory Approval for the Product Improvement in each Party’s respective territory;

               (B) specific tasks, location of work, milestones, estimated timelines, immediate objectives
and long term objectives;

               (C) the global budget for the Joint Subsequent Development and the estimated budget for the
development activities of each Party under the Joint Subsequent Development Plan. The costs of the
development activities of the Parties (the “Joint Subsequent Development Costs”) will be determined
in accordance with Section 4.3(b)(ii) of this Agreement.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 28.

 

               Once agreed by the Parties within the JDC, each Party undertake to use its reasonable
commercial efforts to conduct its development activities under the Joint Subsequent Development
Plan. The Joint Subsequent Development Plan and the Joint Subsequent Development Budget shall be
updated annually by the JDC at a time decided by the JDC and suitable for both Parties’ planning
and budgeting processes, provided however that any update or amendment of the Joint Subsequent
Development Plan and the Joint Subsequent Development Budget shall be approved by both Parties
within the JDC.

               (ii) Determination of Subsequent Development Costs

                    All research and development activities conducted by the Parties under the Joint Subsequent
Development Plan shall be valued as follows:

               (A) internal costs: [ * ];

               (B) external costs: [ * ].

                    In the event the Parties reasonably agree that there is a need to enter into an agreement with
a Third Party having intellectual property rights which would be infringed by the development and
commercialization of the Product Improvement which is the subject matter of the Joint Subsequent
Development (the “Third Party License”), the Parties shall reasonably cooperate to negotiate and
enter into the Third Party License. Any payments to be made to this Third Party under the Third
Party License during the Joint Subsequent Development shall be included in the Joint Subsequent
Development Budget as Joint Subsequent Development Costs.

               (iii) Funding of Joint Subsequent Development

                    All activities undertaken by the Parties pursuant to the Joint Subsequent Development Plan
shall be funded by the Parties in the following proportion : Ipsen shall be responsible for [ * ]
of all Joint Subsequent Development Costs and GTx shall be responsible for [ * ] of all Joint
Subsequent Development Costs, only to the extent the foregoing Joint Subsequent Development Costs
are set forth in the Joint Subsequent Development Budget or revisions thereof. Within [ * ] of
the end of each calendar quarter, each Party will notify the JDC in writing of the Joint Subsequent
Development Costs incurred by such Party during such calendar quarter, and the JDC shall aggregate
such Joint Subsequent Development Costs and allocate them to the Parties in accordance with the
percentages set forth in the foregoing sentence. Where needed in order to reflect such allocated
Joint Subsequent Development Costs, corresponding “true up” payments will be made by the Party
underpaying its share of Joint Subsequent Development Costs to the Party having overpaid its share,
quarterly within [ * ] following the end of each calendar quarter.

               (iv) Disagreement and Opt-out of the Joint Subsequent Development

                    In case of failure of the Parties within the JDC to agree upon the Joint Subsequent
Development Plan, the Joint Subsequent Development Budget and any

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 29.

 

revisions thereof or the terms and conditions of a Third Party License, such disagreement
shall be referred to the Executive Officers. In case the Executive Officers fail to reach an
agreement within [ * ] as from the date such matter was referred to them, then each Party shall
have the right to opt-out of the Joint Subsequent Development, subject to a [ * ] notice period.

                    The decision to opt-out shall be notified to the JDC. The Party exercising this opt-out right
(the “Opt-Out Party”) shall continue all development activities under the Joint Subsequent
Development Plan during the [ * ] notice period, fund the Joint Subsequent Development in
accordance with the provisions of Section 4.3(b)(iii) of this Agreement during such period and
enable the other Party to take over, if the other Party wishes to, such development activities to
avoid any disruption of the Joint Subsequent Development.

                    The Opt-Out Party shall grant to the other Party an exclusive royalty-free license under the
Opt-Out Party’s interest in any Joint Inventions for the sole purpose of the development of the
Product Improvement in the other Party’s territory.

                    After the expiry of the [ * ] notice period, in the event the other Party decides to
continue the development of the Product Improvement at its own cost and expenses, such development
shall be considered as a Sole Subsequent Development and the provisions of Section 4.3(c) shall
apply including the right for the Opt-Out Party to Opt-In under the terms and conditions of this
Section.

               (v) Inventions under the Joint Subsequent Development

                    All Inventions made by the Parties during the course of, or in furtherance of, and as direct
result of the development activities of the Parties in the Joint Subsequent Development shall be
deemed Joint Inventions. For the avoidance of doubt, any Ipsen Invention and GTx Invention which
does not directly result from the development activities under the Joint Subsequent Development
shall be or remain owned by Ipsen or GTx, as the case may be.

               (vi) Commercialization of the Product Improvement developed under a Joint Subsequent
Development

                    Each Party shall have the right to obtain Regulatory Approval and commercialize the Product
Improvement in its respective Territory provided that:

                    (A) each Party shall grant to the other Party a royalty-free, exclusive license on its
interest in the Joint Inventions in the other Party’s territory ;

                    (B) in the event the Parties have entered into a Third Party License, each Party shall pay to
such Third Party any royalty due with respect to each Party’s respective territory. In the event
any other payment would be due to this Third Party, any such payment will be allocated [ * ]
GTx/Ipsen;

                    (C) in the event a Party Controls Patents which are not GTx Patent Rights or Joint Patent
Rights and which would be infringed by the manufacture, use or

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 30.

 

commercialization of the Product Improvement in the other Party’s territory, the Parties shall
negotiate in good faith the terms and conditions of a royalty-bearing license agreement relating to
those Patent Rights for the other Party’s territory.

          (c) Sole Subsequent Development and Opt-in

               (i) Decision for Sole Subsequent Development. In the event that the Parties have not agreed
to jointly perform or fund any Subsequent Development, either Party may pursue and fund at its own
cost and expenses the Subsequent Development (the “Developing Party”), subject to the other
Party’s (the “Non-Developing Party”) right to opt-in in the conduct and funding of the Subsequent
Development (the “Opt-in”).

               (ii) Conduct of the Sole Subsequent Development

                 (1) Reporting. The Developing Party shall provide the JDC with quarterly reports outlining
the results of each completed material pre-clinical and clinical study during the preceding
calendar quarter. Notwithstanding the foregoing, the Developing Party shall not be required to
continue any Sole Subsequent Development or to complete any tasks therein, prior to the time the
other Party exercises its rights to Opt-in.

                 (2) Territorial Restrictions. If Ipsen is the Developing Party, it shall only carry out the
development activities under the Sole Subsequent Development in the European Territory or, outside
the European Territory, but only with the prior written consent of GTx which shall not be
unreasonably withheld or delayed. If GTx is the Developing Party, it shall only carry out
development activities under the Sole Subsequent Development in the GTx Territory or, in the
European Territory, but only with the prior written consent of Ipsen which shall not be
unreasonably withheld or delayed.

                 (3) Development Costs under Sole Subsequent Development. The Developing Party shall be
responsible for all development costs related to such Sole Subsequent Development, subject to
Opt-in by the other Party and sharing of costs pursuant to Section 4.3(c)(iii)(3) below (the “Pre
Opt-in Development Costs”). The Developing Party shall record separately in its books in an
auditable manner, all its Pre Opt-in Development Costs including costs of acquiring ownership or
Control of Patents or Know-How in relation to the New Product.

                 (4) Provision of Information. The Developing Party shall provide to the Non-Developing Party,
on a continuing basis, all relevant information relating to the Sole Subsequent Development through
the JDC (the “Opt-in Information”). Such information shall include but is not limited to: [ * ].
The Non-Developing Party shall only use such Opt-in Information to decide whether to exercise an
Opt-in.

                    If Non-Developing Party does not exercise an Opt-in, such Party shall not use such Opt-in
Information for any other purpose, shall return the same to the Developing Party and shall maintain
its confidentiality, provided that such information qualifies as Know-How of the Developing Party.

                    The Non-Developing Party may request additional information

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 31.

 

which would be reasonably material
for it to make an Opt-in decision and the Developing Party shall supply such information to the
extent it is reasonably available and necessary for the Opt-in decision.

               (5) Third Party License. In the event the Developing Party decides to enter into a Third Party
License, such Developing Party shall so inform in advance the Non-Developing Party and provide the
Non-Developing Party with the opportunity to make any reasonable recommendation with respect to the
terms and conditions of the Third Party License, provided however, that the Developing Party shall
have the sole right to negotiate and execute the Third Party License.

               (6) Inventions under the Sole Subsequent Development. Any Inventions made by the Developing
Party during the course of, or in furtherance of, and as direct result of the development
activities in the Sole Subsequent Development shall be owned by the Developing Party and shall be
considered as an Ipsen Invention if the Developing Party is Ipsen and a GTx Invention if the
Developing Party is GTx.

               (iii) Opt-in.

                 (1) Opt-In Period. With respect to each Sole Subsequent Development Plan, the Non-Developing
Party (the “Opt-in Party”) shall have the right to Opt-in in the performance and the funding of
such Subsequent Development at such times during the performance of the Sole Subsequent Development
as are set forth below (each, an “Opt-in Period”):

                    (A) [ * ] (“Opt-in Period 1”);

                    (B) [ * ] (“Opt-in Period 2”);

                    (C) [ * ] (“Opt-in Period 3”);

                    (D) [ * ] (“Opt-in Period 4”);

                    (E) [ * ] (“Opt-in Period 5”).

                      As used above with respect to a clinical trial, “receipt of data following completion” shall
mean the receipt by the Non-Developing Party of the results from the completed clinical trial at
issue in the form of a final report fully compliant with applicable regulatory requirements, signed
by Chief Research Officer and delivered to the Non-Developing Party.

                      In such event of Opt-in, the Non-Developing Party shall notify its exercise of its right to
Opt-in in writing to the JDC (the “Opt-in Notification”).

                    (2) Extension of the Opt-in Period. In the event a Developing Party is required to supply
additional information pursuant to Section 4.3(c)(ii)(4) above and there are
fewer than [ * ] remaining in the relevant Opt-in Period, such Opt-in Period shall be
extended to

 32.

 

such date that is [ * ] after the provision of such additional information. The
Non-Developing Party may, at its sole discretion, notify the Developing Party in writing before the
expiration of its rights set forth herein, that it waives such rights and such Opt-in rights shall
thereby terminate.

               (3) Opt-in Payment. The Opt-in Party shall reimburse to the Developing Party its share of the
Pre Opt-in Development Costs determined as follows (the “Opt-in Payment”).

(A) Calculation of the Opt-in Payment

        The Opt-in Payment will be equal to the relevant percentage as set forth below applied to (i)
[ * ] and (ii) [ * ]

                         (A) The relevant percentage shall be [ * ] if the Opt-in Party exercises its Opt-in
during Opt-in Period 1;

                         (B) The relevant percentage shall be [ * ] if the Opt-in Party exercises its Opt-in during
Opt-in Period 2;

                         (C) The relevant percentage shall be [ * ] if the Opt-in Party exercises its
Opt-in-during Opt-in Period 3;

                         (D) The Opt-in Payment shall be [ * ] if the Opt-in Party exercises its Opt-in
during Opt-in Period 4;

                         (E) The Opt-in Payment shall be [ * ] if the Opt-in Party exercises its Opt-in during
Opt-in Period 5.

                         (B) Timing of Reimbursement of Pre Opt-in Development Costs. Within [ * ] as from the
Opt-in Notification, the Opt-in Party shall pay to the Developing Party the Opt-in Payment.

                         (C) Disputes. The Opt-in Party may audit Pre Opt-in Development Costs submitted by the
Developing Party pursuant to this Agreement or may appoint internationally-recognized professional
accountants to do so. In the event that the Opt-in Party reasonably disputes specific items
contained in the Developing Party’s calculation of Pre Opt-in Development Costs, the Opt-in Party
shall pay the amounts not in dispute or in question and such disputed or questioned amounts shall
be submitted to the JDC which shall promptly meet or confer to resolve such disputes or questions.
Within [ * ] following resolution of such matters, one Party shall pay or reimburse to the other
Party the appropriate remaining balance. In the event the JDC is not able to resolve a dispute
concerning the Opt-in Payment under this Section, the dispute shall be referred to the Executive
Officers and in case of failure of the Executive Officers to resolve this dispute, the Parties
shall follow the dispute resolution procedure in Article XIV of this Agreement.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 33.

 

               (iv) Joint Development After Opt-in. After any Opt-in, the Parties shall agree upon a Joint
Subsequent Development Plan and a Joint Subsequent Development Budget relating to the development
to be conducted jointly. The provisions of Section 4.3(b) of this Agreement shall apply to the
Subsequent Development as from the Opt-in Notification.

               (v) Non-Exercise of Opt-in by the Non-Developing Party. In the event the Non-Developing Party
does not Opt-in, the Developing Party shall have the right to use, import and commercialize the
Product Improvement in the Developing Party’s territory and in the Non-Developing Party’s
territory, provided, however, that the Developing Party shall commercialize the Product Improvement
in the Non-Developing Party’s territory under a trademark other than the Licensed Trademarks.

                    For this purpose:

                    (A) if the Non-Developing Party is Ipsen, the Parties shall negotiate in good faith the
terms and conditions of an exclusive, royalty-bearing license under any Ipsen Patent Rights which
would Cover the Product Improvement in the European Territory and the GTx Territory ;

                    (B) if the Non-Developing Party is GTx, the Parties shall negotiate in good faith the terms
and conditions of an exclusive, royalty-bearing license under any GTx Patent Rights which would
Cover the Product Improvement in the GTx Territory.

     4.4 Documentation and Data.

          (a) Ipsen Access to GTx Know-How. GTx shall provide Ipsen with copies of the GTx Know-How and
Ipsen shall be authorized to use and reference the same in its applications for Regulatory
Approvals and regulatory compliance activities in relation to such Regulatory Approvals. GTx shall,
upon reasonable request therefore by Ipsen, provide appropriate authorization letters to relevant
regulatory bodies in the European Territory within sixty (60) days from such request to enable
Ipsen to reference any Licensed Product Active Substance Master Files (“ASMFs”) Controlled by GTx
for the purposes of Ipsen’s applications for Regulatory Approval and regulatory compliance
activities in the European Territory. If requested by Ipsen, GTx shall also provide Ipsen with an
appropriate authorization letter from Orion to enable Ipsen to reference all applications or
filings for Regulatory Approvals for Fareston and related ASMFs (as defined and identified in
Article 7.5.3 and Schedule E of the Orion License) for the purpose of applying for and supporting
Regulatory Approval of Licensed Products within the European Territory. In case of Ipsen’s requests
to be provided with copies of GTx Know-How which is controlled by a Third Party and for which Orion
would charge to GTx direct out-of-pocket costs for making such copies and providing such GTx
Know-How, Ipsen shall reimburse GTx for these costs.

          (b) Each Party to Provide the Other With Information Necessary for Development. Each Party
shall provide the other Party, within thirty (30) days from request, copies of, which may be in
partially or wholly electronic form, or access to relevant
documentation, information, data and reports related to its Development in its respective
territory

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 34.

 

of any of the Licensed Products, to the extent such information and documentation are
under the disclosing Party’s Control and possession (and such information and documentation is
freely disclosable), in each case to the extent reasonably necessary or useful to Develop and
Market such Licensed Products in each of the Party’s respective territories

ARTICLE V

LICENSES

     5.1 Non-Exclusive Licenses to Conduct Development. Subject to the terms and conditions of
this Agreement, GTx grants to Ipsen a non-exclusive, royalty-free license under the GTx Patents and
GTx Know-how to conduct development of Licensed Product for any Indication.

     5.2 Exclusive License to Conduct Commercialization Activities. Subject to the terms and
conditions of this Agreement, GTx hereby grants to Ipsen an exclusive (except as to GTx’s rights
under Section 4.2(e) as to the PIN Indication), royalty-bearing license, with the right to grant
sublicenses, under GTx Patents and GTx Know-how to develop, use, sell, have sold, offer for sale,
import, export, and distribute Licensed Product for any Indication within the European Territory.
For clarity, GTx retains rights under the GTx Patents and GTx Know-how to use, sell, have sold,
offer for sale, import, export, and distribute Licensed Product for any Indication within the GTx
Territory.

     5.3 Exclusive License Under Licensed Trademarks. GTx hereby grants to Ipsen an exclusive,
royalty-free license, with the right to grant sublicenses, under Licensed Trademarks, to develop,
use, sell, have sold, offer for sale, and distribute Licensed Product for any Indication within the
European Territory, provided that the license rights relating to the Licensed Trademark pertaining
to the PIN Indication (as long it is different from the Licensed
Trademark for the ADT Indication) shall terminate in the event Ipsen shall fail to make the
Election.

     5.4 Sublicensing. Ipsen may grant sublicenses under Sections 5.1, 5.2 and 5.3 of this
Agreement without GTx’s prior written consent. Any sublicense granted by Ipsen in accordance with
Section 5.1, 5.2 and Section 5.3 of this Agreement shall be granted pursuant to a written agreement
that subjects such sub-licensee to all relevant restrictions, limitations and obligations in this
Agreement. Ipsen shall be responsible for failure by its sub-licensees to comply with, and Ipsen
guarantees to GTx, the compliance by each of its sub-licensees with, all relevant restrictions,
limitations and obligations in this Agreement. In the event of a material default by any
sub-licensee under a sublicense agreement, Ipsen will inform GTx and take such action, after
consultation with GTx, that, in the sublicensing Party’s reasonable business judgment, is required
to address such default.

     5.5 Independent Research. Each Party is free to develop other pharmaceutical products
independent of this Agreement, including without limitation, any other SERM products that are not
Licensed Products. Neither Party has an obligation to disclose
Information relating

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 35.

 

to medicinal chemistry nor other topics relating to SERMs, except to the
extent such Information relates to Licensed Product.

5.6 Obligations With Respect to Competing Products.

          (a) [ * ].

          (b) [ * ].

[ * ].

     5.7 Ipsen’s Right of First Negotiation.

          (a) GTx undertakes to regard Ipsen as its preferential partner for the development, marketing,
sale and distribution of SERMs in the field of the prevention and treatment of prostate cancer or
side effects related thereto or any other Indication in which the Parties jointly develop or
commercialize a Licensed Product (the “Field”). Consequently, in the event GTx acquires, gains
Control or develops a SERM that can be used in the Field, GTx grants to Ipsen a right of first
negotiation to negotiate in good faith an agreement(s) under commercially reasonable terms and
conditions regarding the development, marketing, sale and distribution of such SERM that can be
used in the Field in the European Territory.

          (b) [ * ].

     5.8 GTx’s Right of First Negotiation.

          (a) Ipsen undertakes to regard GTx as its preferential partner for the development, marketing,
sale and distribution of SERMs in the field of the prevention and treatment of prostate cancer or
side effects related thereto or any other Indication in which the Parties jointly develop or
commercialize a Licensed Product (the “Field”). Consequently, in the event Ipsen acquires, gains
Control or develops a SERM that can be used in the Field, Ipsen grants to GTx a right of first
negotiation to negotiate in good faith an agreement(s) under commercially reasonable terms and
conditions regarding the development, marketing, sale and distribution of such SERM that can be
used in the Field in the GTx Territory.

          (b) [ * ].

     5.9 Further Negotiations.

               (a) [ * ].

               (b) [ * ]

               (c) [ * ].

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 36.

 

ARTICLE VI

COMMERCIALIZATION; REGULATORY COMPLIANCE

     6.1 Commercialization and Marketing Responsibilities. Subject to Ipsen’s failure to make the
Election pursuant to Section 4.2(e)(iii) of this Agreement pertaining to the PIN Indication, Ipsen
shall have the sole right and obligation to market all Licensed Products within the European
Territory, and shall therefore have full and exclusive decision making authority with respect to
all Commercialization Activities for all Licensed Product within the European Territory, including
pricing decisions. GTx shall have the sole right and obligation to market all Licensed Products
within the GTx Territory, and shall therefore have full and exclusive decision making authority
with respect to all Commercialization Activities for all Licensed Product within the GTx Territory,
provided that such decisions are consistent with this Agreement. Notwithstanding the foregoing,
each Party shall consider in good faith any comments or concerns expressed by the other Party
regarding such Commercialization Activities that would materially affect the other Party’s
development, marketing, and commercialization of Licensed Products in its respective territory. No
Party shall be required to undertake any activity under this Agreement which it believes, in good
faith, may violate any law.

     6.2 Marketing and Sales Committee. GTx and Ipsen will form a Marketing and Sales Committee at
[ * ] prior to the first anticipated Launch Date of a Licensed Product in the European Territory.
The Marketing and Sales Committee shall be comprised of equal numbers from each Party [ * ] of
reasonably qualified representatives, and shall meet from time to time [ * ], at mutual agreeable
times and locations, to discuss Ipsen’s proposed Marketing and Sales Plan for Licensed Product.
Ipsen will have the final responsibility, with the cooperation and assistance of GTx, for defining
the resources required for the Marketing and sale of the Licensed Product within the European
Territory, and for establishing marketing and promotion strategies with respect to the Licensed
Product and budgets therefor. [ * ].

     6.3 Marketing and Sales Plan and Reports. At [ * ] prior to the first anticipated Launch
Date, Ipsen shall submit to GTx a Marketing and Sales Plan for its review and comment provided that
GTx shall not have approval rights with respect to such Marketing and Sales Plan. The Marketing
and Sales Plan shall set forth, among other items, the projected Annual Net Sales and the projected
advertising and promotion budgets for such year. The Marketing and Sales Plan shall be updated at
least annually by Ipsen and submitted to GTx for review and comment by [ * ] of each calendar
year. In addition, within [ * ] at the end of each calendar year, Ipsen shall provided a
marketing and sales report for each Major Country in which a Licensed Product is launched, which
report shall include a description of sales, marketing and promotion activities and a list of
scientific conferences or other events involving the Licensed Product in which Ipsen has
participated.

     6.4 Medical Inquiries. Ipsen shall respond to all medical questions or inquiries relating to
Licensed Product within the European Territory, which are directed to its respective sales
representatives or other personnel, including Affiliates or sublicensees, unless such question or
inquiry can be answered by reference to EMEA’s or other Regulatory Agencies’ approved labeling and
package insert. Ipsen and GTx agree that they will share with
each other

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 37.

 

all relevant medical information and inquiries pertaining to Licensed Product in
order for each Party to be able to comply with all applicable law, including the requirements of
any Regulatory Agency, and to facilitate the exchange of medical information, each Party agrees to
designate a medical liaison to whom medical questions or inquiries relating to Licensed Product may
be directed.

     6.5 Regulatory Contact. At any time during the term, each Party shall notify the other
Party’s Regulatory Affairs Department upon being contacted by the FDA, the EMEA or any other
Regulatory Agency with respect to Licensed Product and shall specify the nature of such inquiry.
GTx shall retain responsibility for communicating with the FDA provided that GTx agrees to take
into account any reasonable suggestion of Ipsen in the event the inquiry may affect any development
activities conducted by GTx which is supporting the development activities conducted by Ipsen.
During the term, Ipsen shall retain responsibility for communicating with all Regulatory Agencies
in the European Territory provided that Ipsen agrees to take into account any reasonable suggestion
of GTx in the event the inquiry may affect any development activities conducted by GTx for any
Licensed Product.

     6.6 Regulatory Compliance. Ipsen shall comply in all material respects with all applicable
laws, rules, and regulations in the development and commercialization of Licensed Products in the
European Territory under this Agreement. Ipsen shall retain exclusive authority and responsibility
for handling, in any manner it deems appropriate, any disputes or law suits with any Regulatory
Agencies regarding the regulatory status of Licensed Product within the European Territory.
Notwithstanding the foregoing, Ipsen shall consider in good faith any comments or concerns
communicated by GTx to Ipsen regarding such regulatory disputes that would materially affect GTx’s
development, Marketing, and commercialization of Licensed Products in the GTx Territory.

     6.7 Commercialization Efforts. On a country by country basis, during the period commencing
with Regulatory Approval and Pricing and Reimbursement Approval in a Major Country, and for the
remainder of the Term, Ipsen, its Affiliates and/or sublicensees shall use commercially reasonable
efforts to promote, market, distribute and sell the Licensed Product in such Major Country and in
other countries within the European Territory where Regulatory Approval and Pricing and
Reimbursement Approval has been obtained for the Licensed Product. [ * ]:

	 	(i)	 	[ * ];
	 
	 	(ii)	 	[ * ];
	 
	 	(iii)	 	[ * ]
	 
	 	(iv)	 	[ * ]; and
	 
	 	(v)	 	[ * ].

     6.8 Product Launch.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 38.

 

                    (a) Timing of Launch. Ipsen shall use commercially reasonable efforts to launch the Licensed
Product in any Indication [ * ] in every Major Country of the European Territory and other
countries within the European Territory where Ipsen, its Affiliates and/or sublicensees have
obtained Regulatory Approval and Pricing and Reimbursement Approval for the Licensed Product in
such Indication. Notwithstanding the foregoing, Ipsen, its Affiliate or a sublicensee may, acting
in good faith in the exercise of its reasonable business judgment, determine either to delay the
launch of the Licensed Product for use in a given Indication or not to launch the Licensed Product
for use in a given Indication in any given country in the European Territory other than a Major
Country, which decision to delay or not to launch shall not be deemed a failure to use commercially
reasonable efforts. Further, Ipsen’s, its Affiliates’ or a sublicensee’s decision to delay the
launch of the Licensed Product for use in a given Indication in any Major Country for up to [ * ]
after Ipsen or its Affiliates shall have obtained Regulatory Approval and Pricing and Reimbursement
Approval in such country, will not be deemed a failure to use commercially reasonable efforts
pursuant to Section 6.7 to the extent that Ipsen can demonstrate that such delay was attributable
to bona fide business reasons affecting the Licensed Product.

                    (b) Decisions Not to Launch. Notwithstanding the provisions of Section 3.6 of this Agreement,
Ipsen shall promptly notify GTx in writing if Ipsen, its Affiliate or a sublicensee, as applicable,
determines to delay the launch of the Licensed Product for use in a given Indication in any Major
Country after obtaining Regulatory Approval and Pricing and Reimbursement Approval of Licensed
Product therefor. If such decision is due to any reasons other than the potential for, or the
existence of, adverse business effects in such Major Country, or under the conditions set forth in
Section 3.6 of this Agreement, then such decision shall be deemed a material breach of this
Agreement.

     6.9 Commercialization in European Territory. Ipsen shall set all prices for all Licensed
Product within the European Territory, shall obtain Pricing and Reimbursement Approvals for
Licensed Product as may be required, shall be responsible for distribution of each Licensed Product
within the European Territory and shall book all sales for Licensed Product within the European
Territory.

     6.10 Advertising and Promotion. With respect to printed promotional materials or printed
educational materials for Licensed Product within the European Territory, Ipsen shall be solely
responsible for the content of such materials and the preparation thereof, at its sole expense.

     6.11 Additional Support by GTx. If either Party desires the other Party to participate in
marketing activities, such as by participating in global marketing programs, providing medical
liaison support or other Licensed Product specialty support, the Parties shall discuss the proposed
activities. If the Party being requested to participate or provide services agrees in writing to
participate or conduct such activities, the Marketing and Sales Plan shall be revised to reflect
such activities and the Party making the request shall reimburse the other Party on an FTE Cost
plus out-of-pocket cost basis for such support, provided however that in the case such marketing
activities shall benefit both Parties, each Party shall be responsible for paying its own costs and
expense.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 39.

 

ARTICLE VII

SUPPLY OF LICENSED PRODUCT

     7.1 Manufacture and Supply of Licensed Product. Ipsen, GTx and Orion shall enter into a
partial assignment agreement whereby GTx shall assign to Ipsen all rights and obligations
pertaining to the manufacture and the supply of Licensed Product for the European Territory. As the
result of such assignment, Ipsen shall directly purchase the Licensed Product from Orion and GTx
shall have no responsibility whatsoever with respect to such supply.

     7.2 Technology Transfer in Event of Termination of Supply by Orion. In the event that Orion
terminates supply of Licensed Product to GTx and Ipsen for any reason whatsoever, then the Parties
agree to collaborate with one another in good faith to establish one or more alternate
manufacturing sites (either itself or through its Affiliates or Third Parties) to manufacture and
supply Licensed Product in the manner and to the extent necessary and appropriate to meet the needs
of both Parties, provided that in case of disagreement of the Parties on the manufacturing sites,
each Party shall have the right to select such alternate manufacturer(s) and site(s) for its own
supply.

ARTICLE VIII

CONFIDENTIALITY

     8.1 Confidentiality Exceptions. Except to the extent expressly authorized by this Agreement
or otherwise agreed in writing, the Parties agree that, for the term of this Agreement and for [ *
] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise
disclose or use for any purpose other than as permitted in this Agreement any Information and other
information and materials furnished to it by the other Party pursuant to this Agreement; any
provisions of this Agreement that are the subject of an effective order of the Securities Exchange
Commission granting confidential treatment pursuant to the Securities Act of 1934, as amended; and
any Information developed during the term of, and pursuant to, this Agreement (collectively,
“Confidential Information”), except to the extent that it can be established by the receiving Party
that such Confidential Information:

               (a) was already known to the receiving Party, other than under an obligation of
confidentiality, at the time of disclosure by the other Party;

               (b) was generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving Party;

               (c) became generally available to the public or otherwise part of the public domain after
its disclosure and other than through any act or omission of the receiving Party in breach of
this Agreement;

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 40.

 

               (d) was disclosed to the receiving Party, other than under an obligation of
confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose
such information to others; and

               (e) was independently developed by the receiving Party without reliance on, use of or
access to Confidential Information of the other Party as shown by competent documentary
evidence.

     8.2 Authorized Disclosure.

               (a) Each Party may disclose Confidential Information hereunder to the extent such
disclosure is reasonably necessary in filing or prosecuting patent applications, prosecuting or
defending litigation, complying with applicable governmental regulations, or conducting
Pre-Clinical Studies or Clinical Trials; provided, however, that if a Party is required by law
or regulation to make any such disclosures of the other Party’s Confidential Information it
will, except where impracticable for necessary disclosures (for example in the event of medical
emergency), give reasonable advance notice to the other Party of such disclosure requirement
(e.g., filings with the SEC and stock markets) and, except to the extent inappropriate in the
case of patent applications, will use its reasonable efforts to secure confidential treatment
of such Confidential Information required to be disclosed, unless in the opinion of such
disclosing Party’s legal counsel such Confidential Information is legally required to be fully
disclosed. In addition, and with prior notice to the other Party of each Third Party with whom
a confidential disclosure agreement is being entered into, each Party shall be entitled to
disclose, under a binder of confidentiality containing provisions as protective as those of
this Article, Confidential Information to any Third Party on a need to know basis for the
purpose of carrying out the purposes of this Agreement. Nothing in this Article shall restrict
any Party from using for any purpose any Confidential Information independently developed by it
without access to or use of the other Party’s Confidential Information during the term of this
Agreement, or from using Confidential Information that is specifically derived from
Pre-Clinical Studies or Clinical Studies to perform marketing, sales or professional services
support functions as is customary in the pharmaceutical industry.

     (b) Notwithstanding anything herein to the contrary, either Party (and any employee,
representative, or other agent of either Party) may disclose to any and all persons, without
limitation of any kind, the tax treatment and tax structure of the transactions contemplated by
this Agreement and all materials of any kind (including opinions or other tax analyses) that
are provided to it relating to such tax treatment and tax structure. For the purposes of the
foregoing sentence, (i) the “tax treatment” of a transaction means the purported or claimed
federal income tax treatment of the transaction, and (ii) the “tax structure” of a transaction
means any fact that may be relevant to understanding the purported or claimed federal income
tax treatment of the transaction.

     8.3 Survival. Sections 8.1 through 8.3 of this Article shall survive the termination or
expiration of this Agreement for a period of [ * ].

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 41.

 

     8.4 Publications. Except to the extent set forth in Sections 8.2 and 8.5 of this Agreement,
each Party (the “Publishing Party”) shall provide to the other Party (the “Reviewing Party”) the
opportunity to review any proposed scientific/technical publications or scientific presentations
which relate to Toremifene and/or Licensed Product as early as reasonably practical, but at least [
* ] prior to the intended submission for publication (except with the written consent of the
Reviewing Party). The Reviewing Party will provide the Publishing Party with its response to its
request to publish within [ * ] of receipt of such request. In the event that the Reviewing
Party identifies any Confidential Information of the Reviewing Party contained within or referenced
in such publication and the Reviewing Party requests the Publishing Party to remove such
Confidential Information, the Publishing Party shall comply with such request. No publication
shall be made by the Publishing Party without the written agreement of or approval from the
Reviewing Party. However, the failure of the Reviewing Party to respond to such request within such
[ * ] period shall be deemed to be approval of such request and the Publishing Party shall then
be free to proceed with said publication or presentation. Notwithstanding the foregoing,
publications regarding Commercialization activities or that are reasonably needed to effectively
Commercialize a Licensed Product may be made by the Publishing Party even if the Reviewing Party
does not approve, provided that the Reviewing Party may request a reasonable delay on such
publication to seek patent protection on any patentable inventions disclosed therein.

     8.5 Public Disclosures. Subject to the further provisions of this Article VIII, each Party
shall not originate any written publicity, news release or public announcement, whether to the
public or press, concerning this Agreement, including the subject matter to which it relates,
performance under it or any of its terms, or any amendment hereto, without first obtaining the
other Party’s prior written approval, which shall not be unreasonably withheld or delayed, provided
that in the event the Parties shall have previously approved the form of a press release or other
publicly disseminated disclosure, either Party shall be free to disclose publicly substantially the
same information in subsequent public releases without having to obtain other Party’s consent
thereto. Additionally, the Parties acknowledge that as public companies certain information is
required by law to be filed by the Parties with certain agencies or authorities. In connection
herewith, Ipsen acknowledges that GTx will have to file the Agreement with the U.S. Securities and
Exchange Commission (“SEC”) as a “material agreement” of GTx, but GTx shall do so under a request
for confidential treatment which shall be submitted to Ipsen for its approval (not to be
unreasonably withheld or delayed) prior to submission. Once information is disclosed to the SEC,
any similar information which is not subject to confidential treatment may be disclosed by GTx in
subsequent public filings or in public disclosures without having to first obtain Ipsen’s prior
written approval.

ARTICLE IX

OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

     9.1 Ownership. Each Party shall solely own, and that Party alone shall have the right to
apply for, Patents for any Ipsen Inventions or GTx Inventions. Joint Inventions shall be owned
jointly by GTx and Ipsen, without a duty of accounting. For clarity, either Party shall be free to
grant licenses or other rights under Joint Inventions, to the extent consistent with the

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 42.

 

licenses granted to the other Party pursuant to this Agreement. The law of joint ownership of
inventions of the United States shall apply to any joint ownership of Patents claiming joint
inventions of the Parties.

     9.2 Invention Disclosures. Each Party shall promptly provide to the other Party any Invention
disclosure submitted in the normal course of its operations and disclosing an Invention arising
during the course of and pursuant to this Agreement.

     9.3 Disclosure of Provisional and Non-Provisional Patent Applications. Each Party shall
provide to the other, within a reasonable time prior to filing, a copy of each non-provisional
patent application proposed to be filed by such Party disclosing an Invention arising during the
course of and pursuant to this Agreement and each Party shall provide to the other, immediately
after filing, a copy of each provisional patent application actually filed by such Party disclosing
an Invention. The contents of any patent application submitted to either Party pursuant to this
Section 9.3 covering an Invention solely owned by such Party shall be deemed the Confidential
Information of the Party providing such application.

     9.4 Patent Filings.

          (a) Ipsen Patent, GTx Patent and Joint Patent Filings. Each Party, at its sole discretion,
responsibility, and cost shall prepare, file, prosecute and maintain its own Patents. GTx shall
file, prosecute and maintain Patents to cover Joint Inventions. Ipsen and GTx shall pay fifty
percent (50%) of all costs associated with the preparation, prosecution and maintenance of Joint
Patents unless the Parties otherwise agree. The determination of the countries in which to file
Joint Patents shall be made jointly by the Parties. GTx shall have the right to direct and control
all material actions relating to the prosecution or maintenance of Joint Patents, subject to
Ipsen’s ability to comment on such filings and GTx’s reasonable consideration of such comments.
GTx shall provide prior written notice to Ipsen of the countries in which it intends to file,
including conflict proceedings, reexaminations, reissuance, oppositions and revocation proceedings,
provided, however, that Ipsen shall have the right to file or continue prosecution in countries in
which GTx determines it wishes to abandon or not file such Joint Patent.

          (b) Ipsen and GTx Patent Strategy. GTx shall keep Ipsen apprised of the status of each Joint
Patent for which it is responsible and shall seek the advice of Ipsen with respect to patent
strategy and drafting applications and shall give reasonable consideration to any suggestions or
recommendations concerning the preparation, filing, prosecution, maintenance and defense thereof.
The Parties shall cooperate reasonably in the prosecution of all Joint Patents and other GTx
Patents covering Licensed Products and shall share all material information relating thereto,
including all material communications from patent offices, promptly after receipt of such
information. If the Parties are unable to agree as to any aspect of patent prosecution of a Joint
Patent or a Patent covering a Licensed Product, each Party at its expense shall be free to take
whatever action it deems appropriate to protect the Joint Invention or Licensed Product, including
the filing of patent applications subject to prior notification of the other Party. If, during the
term of this Agreement, the filing Party intends to allow any Patent covering a Licensed Product to
which the Party has license rights under this Agreement to lapse

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 43.

 

or become abandoned without having first filed a substitute, the filing Party shall, whenever
practicable, notify the other Party of such intention at least sixty (60) calendar days prior to
the date upon which such Patent shall lapse or become abandoned, and the other Party shall
thereupon have the right, but not the obligation, to assume responsibility for the prosecution,
maintenance and defense thereof and all expenses related thereto.

          (c) Diligence in Patent Filings. The Parties agree to use reasonable efforts to ensure that
any Patent filed outside of the United States prior to a filing in the United States will be in a
form sufficient to establish the date of original filing as a priority date for the purposes of a
subsequent filing in the United States.

          (d) Cooperation by Ipsen and GTx in Patent and Regulatory Filings. The Parties shall
cooperate in order to avoid loss of any rights that may otherwise be available to the Parties under
the U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary
Certificate of Protection of the Member States of the European Union and other similar measures in
any other country. Without limiting the foregoing, GTx shall notify Ipsen upon receipt of
Regulatory Approval to market a Licensed Product in the United States, and Ipsen shall notify GTx
upon receipt of Regulatory Approval to market a Licensed Product in the EU. Both Parties agree to
timely file such applications as they feel are appropriate or required to extend the patent term of
the GTx Patents pertaining to Licensed Product. The obligations set forth in this Section shall
apply with respect to patent term extensions, or the equivalent, in any other country. Any
application for patent term extension of the GTx Patents in the United States shall be made by GTx.

     9.5 Third Party Patent Rights. Except as expressly provided in Section 10.1 of this
Agreement, neither Party makes any warranty with respect to the validity, perfection or dominance
of any Patent or other proprietary right or with respect to the absence of rights in Third Parties
which may be infringed by the manufacture or sale of any Licensed Product. Each Party agrees to
bring to the attention of the other Party any Patent or Patent application it discovers, or has
discovered, and which relates Toremifene or any Licensed Product.

     9.6 Enforcement Rights.

          (a) Notification of Infringement. If either Party learns of any infringement or threatened
infringement by a Third Party of a GTx Patent or a Joint Patent, such Party shall promptly notify
the other Party and shall provide such other Party with all available evidence of such
infringement.

          (b) Enforcement. GTx shall have the right, but not the obligation, to institute, prosecute
and control at its own expense any action or proceeding with respect to infringement by any Third
Party of any GTx Patents (including Joint Patents) covering the manufacture, use, importation,
exportation, sale or offer for sale of Licensed Product by reason of the manufacture, use or sale
of products competitive with Licensed Product, using counsel of its own choice. Ipsen shall have
the right, at its own expense, to be represented in any such action by counsel of its own choice.
If GTx fails to bring such an action or proceeding or otherwise take appropriate action to abate
such infringement within a period of one hundred

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 44.

 

eighty (180) calendar days of notice by Ipsen to GTx requesting action, Ipsen will have the
right but not the obligation to bring and control, at its expense, any such action or proceeding
relating to GTx Patents by counsel of its own choice and GTx will have the right to be represented
in any such action by counsel of its own choice and at its own expense.

          (c) Settlement with a Third Party. The Party that controls the prosecution of a given action
shall also have the right to control settlement of such action; provided, however, that if one
Party controls such action, no settlement shall be entered into without the written consent of the
other Party if such settlement would materially and adversely affect the interests of such other
Party. If the other Party shall refuse to grant such consent, then the dispute will be resolved
pursuant to Article XIV.

          (d) Damage Award or Settlement Payments. Any damage award or settlement payments made to
either or both of GTx or Ipsen in connection with any such action relating to infringement of a GTx
Patent or a Joint Patent, whether obtained by judgment, settlement or otherwise shall be allocated,
(i) first, to the Party which initiated and prosecuted the action to recoup all of its costs and
expenses incurred in connection with the action, (ii) second, to the other Party, to recover all of
its costs and expenses incurred in connection with the action, and [ * ].

          (e) Defense and Settlement of Third Party Claims. If a Third Party asserts that a patent,
trademark or other intangible right owned by it is infringed by the manufacture, use, or sale of
any Licensed Product, GTx shall have the first right, but not the obligation, to defend the Parties
against any claim by a Third Party that the development, use, sale, offer for sale, export or
import of Licensed Product in the European Territory infringes Third Party intellectual property
rights but no settlement may be entered into without the written consent of Ipsen if such
settlement would materially and adversely affect Ipsen’s interests in any Licensed Product. Ipsen
shall have the right to participate in the defense of such claim at its cost and expense but shall
not take any position inconsistent with GTx’s position on such issues. In the event GTx chooses at
in its sole discretion not to defend such suit, Ipsen shall have the right but not the obligation
to defend such suit, provided that Ipsen shall not settle any action pursuant to this Section
without GTx’s consent, such consent not to be unreasonably withheld.

     9.7 Allocation of Patent Expenses. On a country-by-country basis, Patent Expenses arising
from GTx Patents shall be borne solely by GTx, Patent Expenses arising from Ipsen Patents shall be
borne solely by Ipsen and Patent Expenses arising from Joint Patents shall be borne equally by the
Parties, unless otherwise agreed.

     9.8 Assignment of Joint Patents. Neither Party may assign its rights under any Joint Patent
except with the prior written consent of the other Party; provided, however, that either Party may
assign such rights without consent to an Affiliate or other permitted assignee under this Agreement
in connection with a merger or similar reorganization or the sale of all or substantially all of
its assets.

     9.9 Trademarks.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 45.

 

          (a) The Licensed Product will be marketed in the European Territory under the Licensed
Trademark, provided, however that (i) if the Licensed Product is subject to a centralized
Regulatory Approval process with the EMEA, the Licensed Product will be marketed in the European
Territory under the Licensed Trademark if approved by the EMEA or any other trademark as determined
jointly by the Parties and approved by the EMEA and (ii) in specific countries of the European
Territory where the use of the Licensed Trademark is not permitted by law or is not appropriate
including for reasons relating to language or custom, Ipsen shall have the possibility to use a
different trademark, subject to GTx’s prior written approval which shall not be unreasonably
withheld or delayed. GTx shall be responsible for securing and for maintaining registrations for
the Licensed Trademark in the European Territory and shall use reasonable commercial efforts in
that regard, provided, however, that GTx shall not be deemed to have breached this
Agreement if it is unable to obtain registration of the Licensed Trademark in every country in the
European Territory. In the event, despite its reasonable commercial efforts, GTx is unable to
obtain or maintain registrations for the Licensed Trademark in some country(ies) in the European
Territory, the Parties shall negotiate in good faith concerning the use of such other trademarks as
may be available for marketing the Licensed Product in those countries.

          (b) GTx and Ipsen shall cooperate with each other and use reasonable efforts to protect the
Licensed Trademark from infringement by Third Parties. Without limiting the foregoing, each Party
shall promptly notify the other Party of any known, threatened or suspected infringement, imitation
or unauthorized use of or unfair competition relating to the Licensed Trademark. GTx shall have
the first right to determine in its discretion whether to and to what extent to institute,
prosecute and/or defend any action or proceedings involving or affecting any rights relating to the
Licensed Trademark. Upon GTx’s reasonable request, Ipsen shall cooperate with and assist GTx in any
of GTx’s enforcement efforts with respect to the Licensed Trademark. GTx shall promptly inform
Ipsen if GTx elects not to take action against any actual or suspected infringement of the Licensed
Trademark, in which case, Ipsen shall then have the right, but not the obligation, to bring or
assume control of any action against the allegedly infringing third party as Ipsen determines may
be necessary, provided, however, that Ipsen shall not enter into any settlement or
compromise of any claim relating to the Licensed Trademark without the prior written consent of
GTx. In the event that Ipsen brings or assumes control of any such action, then GTx agrees to
reasonably assist Ipsen in connection therewith. In either case, the Party that initiated and
prosecuted, or maintained the defense of the action shall bear all of the costs and expenses
(including reasonable attorneys’ fees) incurred in connection with the action and shall be entitled
to recoup those amounts in the event of recovery, by settlement or otherwise. The amount of any
recovery remaining shall be shared equally by the Parties.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 46.

 

ARTICLE X

REPRESENTATIONS AND WARRANTIES

     10.1 Representations and Warranties.

               (a) Parties’ Representations and Warranties. Each of the Parties hereby represents and
warrants to the other Party as follows:

                    (i) Parties’ Authority to Enter Into Agreement. This Agreement is a legal and valid
obligation binding upon such Party and enforceable in accordance with its terms. The execution,
delivery and performance of the Agreement by such Party does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a Party or by which it is bound, nor
violate any law or regulation of any court, governmental body or administrative or other agency
having jurisdiction over it, provided that for purposes hereof, Each Party expressly represents and
warrants that it has the full power and authority to enter into this Agreement and to carry out the
obligations contemplated hereby.

                    (ii) Compliance with Laws. It shall comply with all applicable local, state, national,
regional and governmental laws and regulations relating to its activities under this Agreement.

                    (iii) No Debarment. It has not been and will not be debarred under Section 306 of the Federal
Food, Drug and Cosmetic Act, 21 U.S.C. 335a(a) or (b). In the event that such Party becomes aware
of, or receives notice of, the debarment of any individual, corporation, partnership, or
association performing activities which relate to the Products, it shall notify the other Party
immediately and address the issue as directed by the other Party.

               (b) GTx Representations and Warranties to Ipsen. GTx hereby represents and warrants to
Ipsen as follows:

                    (i) GTx Patents. GTx warrants and represents that, to the best of its knowledge as of the
Effective Date, (A) Exhibit A of this Agreement sets forth all of GTx Patents as of the Effective
Date which are directed to the composition of matter or use of Toremifene in Licensed Products,
(B) the GTx Patents which have been granted and for which any period for filing a protest shall
have expired are valid, in full force and enforceable, (C) there are no existing valid Third Party
patents in the European Territory that might be infringed by the sale of the Initial Products by
Ipsen under this Agreement and (D) the use and/or sale of the Licensed Products in the ADT and PIN
Indications in the European Territory will not in the absence of a license from GTx infringe any
patents owned or Controlled by GTx other than the GTx Patents

                    (ii) Infringement. As of the Effective Date, it has not received any notices of infringement
or any written communications relating in any way to a possible infringement with respect to
Initial Products, and it is not aware that the manufacture, use or sale

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 47.

 

of Initial Products as set forth herein infringes any Third Party patent rights which have not
been licensed to GTx.

                    (iii) GTx’s Power and Authority. GTx expressly represents and warrants that it has the full
power and authority to enter into this Agreement and to carry out the obligations contemplated
hereby. GTx expressly represents and warrants that to its knowledge it owns (in whole or in part)
or otherwise Controls all Patents and Know-How that are the subject of the licenses granted to
Ipsen herein.

                    (iv) UTRF and Orion Consents. GTx expressly represents and warrants that no consents are
required to be obtained from UTRF and Orion under the GTx Licenses relating to the execution of
this Agreement other than the consent of Orion for the assignment of supply rights to Ipsen for the
European Territory.

                    (v) GTx Prior Obligations. As at the Effective Date, GTx is obligated under only the GTx
Licenses to pay to any Third Party royalties with respect to Licensed Products for any Indication.

                    (vi) GTx Licenses. GTx warrants that as of the Effective Date, (i) the GTx Licenses are in
full force and in effect in accordance with their terms, (ii) GTx is not in default or breach in
any material respect of the GTx Licenses and (iii) to GTx’s knowledge, there is no cause of early
termination of the GTx Licenses. GTx shall (i) comply with and observe in all material respects its
obligations under the GTx Licenses and (ii) not terminate or otherwise modify any terms or
conditions of the GTx Licenses in any manner that would materially adversely affect Ipsen’s rights
under this Agreement without the prior written consent of Ipsen.

               (c) Ipsen Representations and Warranties to GTx. Ipsen hereby represents and warrants to
GTx as follows:

                    (i) Acceptance of Obligations and Duties. Ipsen acknowledges receipt of copies of the GTx
Licenses and agrees to be bound by the terms thereof as far as these terms are applicable to Ipsen.

                    (ii) Ipsen’s Power and Authority. Ipsen expressly represents and warrants that it has the
full power and authority to enter into this Agreement and to carry out the obligations contemplated
hereby.

     10.2 Performance by Affiliates. The Parties recognize that each Party may perform some or all
of its obligations under this Agreement through Affiliates, provided, however, that each Party
shall remain responsible for and be a guarantor of the performance by its Affiliates and shall
cause its Affiliates to comply with the provisions of this Agreement in connection with such
performance.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 48.

 

ARTICLE XI

INFORMATION AND REPORTS

     11.1 Information and Reports During Development and Commercialization. Ipsen and GTx will
disclose and make available to each other upon written request and without charge (other than
reimbursement to the providing Party for reasonable duplicating, postage and related expenses) all
pre-clinical, clinical, quality, regulatory, commercial, marketing, promotion, pricing, sales and
other Information, including copies of all preclinical and clinical reports, known by Ipsen or GTx
that directly concern Licensed Product, as provided for in this Agreement. Each Party will use
commercially reasonable efforts to disclose to the other Party all significant Information relating
to Licensed Product promptly after it is learned or its significance is appreciated. GTx shall own
and maintain the combined database of clinical trial data accumulated from all clinical trials of
Licensed Product and of adverse drug event information for all Licensed Product. Without
limitation of the foregoing, each Party shall supply to the other the Information required by the
other Party and reasonably requested by it (either as a routine practice or as a specific request)
for purposes of compliance with regulatory requirements relating to Licensed Product.

     11.2 Complaints. Each Party shall maintain a record of all complaints it receives with
respect to any Licensed Product and shall inform the other Party of the receipt of such complaint.

     11.3
Safety Data Exchange Agreement. Within [ * ] calendar days of the Effective Date, the
Parties and Orion will negotiate in good faith and execute a pharmacovigilance safety data exchange
agreement, which shall include adverse event reporting, with terms and conditions that are
customary in the industry.

     11.4 Records of Revenues and Expenses.

          (a) Maintenance; Audits. Each Party shall keep complete and accurate records which are
relevant to revenues, costs, reimbursements and other payments to be made under this Agreement,
including, without limitation, information used to calculate Net Sales, and royalty calculations,
existing Third Party royalty payments due for licenses granted by such Third Parties, other license
fees and other payments and royalties due under this Agreement. In connection herewith, Ipsen
agrees that it shall maintain accurate records reflecting the actual purchases of Licensed Product
made from Orion during the term of this Agreement, on a country by country basis, and the sales of
each Licensed Product in each such country, including copies of invoices reflecting purchases of
Licensed Product and other data supporting the consumption of such Licensed Product in each of the
countries within the European Territory. Such records shall be open at the location(s) where such
records are maintained, upon reasonable notice, during regular business hours and under obligations
of confidence, for a period of [ * ] from creation of individual records. Upon the written
request of GTx, Ipsen and GTx shall agree on a mutually acceptable date on which to permit an
independent certified public accountant firm of an internationally recognized standing and selected
by GTx to examine such records at its expense (not more often than once each year), for the sole
purpose of verifying the accuracy of

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 49.

 

calculations, amounts and classifications of such revenues, costs or payments made under this
Agreement. The accounting firm shall disclose to GTx and Ipsen whether the calculations were
correct or incorrect, the specific details concerning any discrepancies and such other information
that should properly be contained in any reports required under this Agreement. In the absence of
material discrepancies (i.e., in those instances where discrepancy is less than [ * ] of the
amounts payable under this Agreement) identified in any such audit, the accounting expenses shall
be paid by GTx. If material discrepancies are identified by the independent accountant, the audited
Party shall bear all accounting expenses. If such accounting firm concludes that additional
royalties or other amounts were owed by Ipsen, Ipsen shall promptly pay any amounts due to the GTx.
Upon the expiry of [ * ] following the end of any calendar year for which Ipsen made payment in
full of all royalties and other amounts payable with respect to such calendar year, and in the
absence of gross negligence or willful misconduct of Ipsen or a contrary finding by an accounting
firm pursuant to this Section, such calculation shall be binding and conclusive upon the Parties
and Ipsen shall be released from any liability or accountability with respect to royalties or other
payments for such calendar year.

          (b) Any records or accounting information received by a Party from the other Party shall be
Confidential Information for purposes of Article VIII of this Agreement. Results of any such audit
shall be provided to both Parties, subject to Article VIII of this Agreement.

ARTICLE XII

TERM AND TERMINATION

     12.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner
terminated as provided in this Article XII of this Agreement, (a) the provisions relating to
development and Commercialization shall continue in effect until the Parties are not developing or
Commercializing any Licensed Product within the European Territory; and (b) the provisions relating
to Commercialization shall continue in effect until the date on which Ipsen is no longer obligated
to pay Royalty Payments to GTx on Net Sales of Licensed Product.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 50.

 

     12.2 Termination for Material Breach.

          (a) Right to Terminate. Subject to the provisions of this Section, if either Party (the
“Breaching Party”) shall have committed a material breach and such material breach shall remain
uncured and shall be continuing for a period of [ * ] following receipt of notice thereof by the
other Party (the “Non-Breaching Party”), then, in addition to any and all other rights and remedies
that may be available, the Non-Breaching Party shall have the right to terminate this Agreement
effective upon the expiration of such thirty (30) calendar day period. Any such notice of alleged
material breach by one party (the “Accusing Party”) shall include a reasonably detailed description
of all relevant facts and circumstances demonstrating, supporting and/or relating to each such
alleged material breach by the other party (“Accused Breaching Party”).

          (b) Excuse. If the Accused Breaching Party, upon written notice delivered to the Accusing
Party prior to the expiration of such [ * ] period, shall assert in good faith that any such
alleged material breach described in the Accusing Party’s notice, whether in payment of moneys or
otherwise, was not a material breach, or was excused by reason of material failure of performance
by the other Party or Third Parties or by reason of Force Majeure, or shall otherwise in good faith
dispute such alleged material breach, then the Parties shall continue to perform under this
Agreement, subject to all of its terms and conditions, and the matter shall be resolved pursuant to
the provisions of Article XIV of this Agreement. In such event, the Accusing Party shall not be
entitled to terminate this Agreement pursuant to this Section unless and until (i) it shall be
determined pursuant to Article XIV of this Agreement that the Accused Breaching Party has committed
a material breach and (ii) such material breach has not been cured prior to such determination
pursuant to Article XIV of this Agreement. To the extent that it is determined pursuant to a final
and non-appealable decision under Article XIV of this Agreement that the Accused Breaching Party
did commit a material breach and failed to cure the same within the period provided for in clause
(ii) above, then the Accusing Party may immediately terminate this Agreement and, in addition to
all damages determined pursuant to the provisions of Article XIV of this Agreement to be due and
owing from the Breaching Party to the Non-Breaching Party under this Agreement, the Breaching Party
shall be liable for the Non-Breaching Party’s reasonable attorneys’ fees incurred in connection
with resolving such matter pursuant to Article XV of this Agreement. If a final and non-appealable
decision is made under Article XIV of this Agreement that no material breach was committed by the
Accused Breaching Party, then the decision maker under Article XIV of this Agreement may elect to
require the Accusing Party to pay the Accused Breaching Party’s attorneys’ fees incurred in
connection with resolving such matter if he or she determines that the Accusing Party’s basis for
providing a notice of material breach to the other Party was not reasonable.

          (c) Termination. If the Non-Breaching Party terminates this Agreement pursuant to the
provisions of Sections 12.2(a) and (b) of this Agreement, then the following provisions shall
apply:

               (i) If the Non-Breaching Party that terminates this Agreement is Ipsen, then Ipsen’s license
under Section 5.2 of this Agreement shall survive, subject, however, to the rights and interests of
Orion and UTRF under the GTx Licenses. The Royalty Payments

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 51.

 

required to be paid to GTx by Ipsen under Article III of this Agreement shall survive but
shall be offset by any damages incurred by Ipsen in connection with such material breach.

               (ii) If the Non-Breaching Party that terminates this Agreement is GTx, then the effects of
termination as set forth in Section 12.5 of this Agreement shall apply.

          (d) Remaining Obligations. Except where expressly provided for otherwise in this Agreement,
termination of this Agreement shall not relieve the Parties hereto of any liability, including any
obligation to make payments hereunder, which accrued hereunder prior to the effective date of such
termination, nor preclude any Party from pursuing all rights and remedies it may have hereunder or
at law or in equity with respect to any breach of this Agreement nor prejudice any Party’s right to
obtain performance of any obligation.

     12.3 Termination by Ipsen. Ipsen may terminate this Agreement upon the following
circumstances :

               (a) For any reason whatsoever, with [ * ] prior written notice to GTx; provided, however,
that in the event that termination is the result of a legitimate and documented concern over
Safety, termination shall be effective [ * ] after written notice to GTx; and

               (b) With [ * ] prior written notice, in case of early termination of the Orion License
(except in the event of the termination of the Orion License due to Orion’s breach pursuant to
Section 21.2.2 of the Orion License) and/or the UTRF License (on account of the PIN Indication);
provided, however, that in the case of the termination of the Orion License (except in the event of
the termination due to Orion’s breach as herein provided) and/or the UTRF License (on account of
the PIN Indication), GTx shall use its commercially reasonable efforts to ensure that, upon
request from Ipsen, Orion and/or UTRF will agree to discuss with Ipsen with a view to negotiate the
terms and conditions under which Orion and/or UTRF would be willing to collaborate with regard to
the further development and commercialization of Licensed Product in the Indications in which GTx
and Ipsen were previously developing and commercializing such Licensed Products, provided that any
such further development and/or commercialization of the Licensed Products by Orion and Ipsen would
be subject to and conditioned on a definitive written agreement to be negotiated between and
executed by Orion and Ipsen.

     12.4 Bankruptcy. Either Party may terminate this Agreement, in whole or in part as
applicable, effective immediately upon receipt of written notice to the other Party if such other
Party is adjudged bankrupt or has had filed against it any petition under any bankruptcy,
insolvency or similar laws or has had a receiver appointed for its business or property, and in
each case such petition or appointment of receiver shall not have been dismissed within ninety (90)
days of such filing or appointment, or each Party makes a general assignment for the benefit of its
creditors.

     12.5 Effect of Termination by GTx Under Section 12.2 of this Agreement or Termination by Ipsen
Under Section 12.3 of this Agreement. If GTx terminates this Agreement for Material Breach by
Ipsen pursuant to Section 12.2 of this Agreement or if Ipsen

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 52.

 

terminates this Agreement pursuant to Section 12.3 of this Agreement, Ipsen shall continue to
be obligated during the termination notice period to perform all of its obligations under this
Agreement, including its obligation to pay Initial Development Expenses. In addition, as a result
of any such termination:

	 	(a)	 	[ * ]
	 
	 	(b)	 	[ * ]
	 
	 	(c)	 	[ * ]
	 
	 	(d)	 	[ * ]
	 
	 	(e)	 	[ * ]
	 
	 	(f)	 	[ * ]
	 
	 	(g)	 	[ * ] and
	 
	 	(h)	 	[ * ]

     12.6 Permitted or compulsory assignment other than to Affiliate or by merger or
reorganization. [ * ].

     12.7 Surviving Rights. The rights and obligations set forth in this Agreement shall extend
beyond the term or termination of the Agreement only to the extent expressly provided for herein,
or the extent that the survival of such rights or obligations is necessary to permit their complete
fulfillment or discharge. Without limiting the foregoing, Sections 3.10, 8.1, 8.2, 8.3, 9.1, 11.4,
12.2 and 12.3 (as to activities occurring during the term of the Agreement), 12.4, 12.5, 12.6,
12.7, 13.1-13.4 (if applicable to such termination),13.5, and Articles 14 and 15 shall survive
expiration or termination of this Agreement.

ARTICLE XIII

INDEMNIFICATION

     13.1 Ipsen and GTx. Ipsen and GTx shall each indemnify, defend and hold harmless the other
Party and their officers, directors, agents, employees and Affiliates against and from any and all
Third Party actions, proceedings, claims, suits, judgments, expenses (including reasonable attorney
fees), losses, liabilities and damages (collectively, “Indemnification Claims” or “Claims”) which
the other Party may incur or suffer to the extent such arise out of or are based upon (a) the
material breach by such Party in the performance of any obligation of a Party in this Agreement or
of any warranty, representation, or agreement made by such Party in this Agreement, (b) the
intentional misconduct of such Party, its Affiliates, or their respective officers, directors or
employees (each an “Actionable Party”), or (c) the negligent acts or

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 53.

 

omissions of an Actionable Party, but only to the extent such negligent
acts or omissions materially contributed to the Claims.

     13.2 Ipsen. Ipsen further agrees to defend, indemnify and hold harmless GTx, its officers,
directors, agents, employees and Affiliates (“GTx Indemnitees”), from and against any Claims
relating to personal injuries (including death) or product liability or other loss or damage by
Third Parties resulting from or relating to the packaging, labeling, sale, use, storage,
transportation, distribution or handling of Licensed Product in the European Territory; provided,
however, that Ipsen shall not be required to defend, indemnify, or hold harmless GTx Indemnitees
from any such Claims to the extent they result from GTx’s, its officers’, directors’, employees’ or
Affiliates’ gross negligence or willful misconduct, GTx’s sales of Licensed Product in the GTx
Territory or material breach of this Agreement.

     13.3 GTx. GTx further agrees to defend, indemnify and hold harmless Ipsen, its officers,
directors, agents, employees and Affiliates (“Ipsen Indemnitees”), from and against any Claims
relating to personal injuries (including death) or product liability or other loss or damage by
Third Parties resulting from or relating to packaging, labeling, sale, use, storage,
transportation, distribution or handling of Licensed Product in the GTx Territory, provided,
however, GTx shall not be required to defend, indemnify of hold harmless Ipsen Indemnitees from any
such Claims to the extent they result from Ipsen’s, it officers’, directors’, employees’ or
Affiliates’ gross negligence or willful misconduct, Ipsen’s sales of Licensed Product in the
European Territory or material breach of this Agreement.

     13.4 Procedure. The Party seeking indemnification (the “Indemnified Party”) shall inform the
other Party promptly of any such Claim which is brought against it and shall, to the extent such
Claim is brought by a Third Party, at the other Party’s request, cooperate fully with the other
Party in defending such Claim. The Indemnified Party, at its expense, shall have the right to
advise and consult on and participate in any related suit or proceeding, subject to the ultimate
control of the Indemnifying Party. The other Party (“Indemnifying Party”) shall have full control
over the suit or proceedings, including the right to settle, through counsel of its choice who is
reasonably acceptable to the Indemnified Party; provided, however, the Indemnifying Party will not,
absent the consent of the Indemnified Party (which consent will not be unreasonably withheld),
consent to the entry of any judgment or enter into any settlement that (a) provides for any relief
other than the payment of monetary damages for which the Indemnifying Party shall be solely liable
and (b) where the claimant or plaintiff does not release the Indemnified Party from all liability
in respect thereof. If the Indemnifying Party declines to accept control of the defense of such
claim or action, the Indemnified Party may retain counsel at the expense of the Indemnifying Party
and control the defense of the claim or action, provided that the claim or action may not be
settled by the Indemnified Party without the approval of the Indemnifying Party, which approval
shall not be unreasonably withheld or delayed. Any payment made by the Indemnifying Party to
settle any claim or action hereunder shall be at its own cost and expense.

     13.5 Insurance.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 54.

 

          (a) Each Party agrees during the term of the Agreement and for a period of at least three (3)
years thereafter to maintain commercial general liability insurance covering each Party’s
activities contemplated in this Agreement on a claims made form having limits of not less than and
[ * ] per occurrence. All insurance companies must be rated A or better in the most recent AM
Best Rating Guide. Each party, upon request, agrees to provide the other Party with a certificate
of insurance evidencing its retention of such insurance coverage and any updates thereto.

          (b) Each Party shall ensure that their subcontractors, if any, are properly insured against
the risks related to their own activities, for damages of any kind, caused to the other Party or to
Third Party, for an amount proportionate to the activities carried out by such subcontractors
hereunder. The insurance must be subscribed with a financially sound company of international
repute.

ARTICLE XIV

DISPUTE RESOLUTION

     14.1 Disputes. The Parties recognize that disputes as to certain matters may from time to
time arise during the term of this Agreement that relate to either Party’s rights and/or
obligations hereunder. It is the objective of the Parties to establish procedures to facilitate
the resolution of disputes arising under this Agreement in an expedient manner by mutual
cooperation and without resort to litigation. To accomplish this objective, the Parties agree to
follow the procedures set forth in this if and when a dispute arises under this Agreement.

     14.2 Disputes Referred First to Executive Officers. Unless otherwise specifically recited in
this Agreement, disputes between the Parties shall be referred to the Parties’ respective Executive
Officers or their successors, for attempted resolution by negotiations within fourteen (14)
calendar days after such issue is submitted for resolution to such officers.

     14.3 Resolution of Dispute by Alternate Means. In the event the designated Executive Officers
are not able to resolve such dispute, such dispute shall be resolved through binding arbitration,
which arbitration may be initiated by either Party at any time after the conclusion of such period,
on the following basis:

               (a) The place of arbitration shall be [ * ].

               (b) The arbitration shall be made in accordance with the [ * ].

               (c) The governing law shall be [ * ] .

               (d) Judgment upon the award rendered by such arbitrator shall be binding on the Parties
and may be entered by any court or forum having jurisdiction.

               (e) Either Party may apply to the arbitrators for interim injunctive relief until the
arbitration award is rendered or the controversy is otherwise resolved. Further,
either Party also may, without waiving any remedy under this Agreement, seek from any

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 55.

 

court having jurisdiction any injunctive or provisional relief necessary to protect the rights
or property of such Party pending the arbitration award.

               (f) [ * ].

               (g) Each Party shall bear its own costs and expenses and attorneys’ fees and an equal
share of the arbitrators’ and any administrative fees of arbitration.

               (h) Except to the extent necessary to confirm an award or as may be required by law,
neither Party nor any arbitrator may disclose the existence, content, or results of an
arbitration without the prior written consent of both Parties.

               (i) In no event shall an arbitration be initiated after the date when commencement of a
legal or equitable proceeding based on the dispute, controversy or claim would be barred by the
applicable statute of limitations.

     14.4 Patent and Trademark Dispute Resolution. Any dispute, controversy or claim relating to
the scope, validity, enforceability or infringement of any patent rights covering the manufacture,
use or sale of any Licensed Product or of any trademark rights relating to any Licensed Product
shall be submitted to a court of competent jurisdiction in the territory in which such Patent or
trademark rights were granted or arose.

     14.5 Injunctive Relief. Nothing herein may prevent either Party from seeking preliminary
injunction or temporary restraint order in order to prevent any Confidential Information is
disclosed without appropriate authorization under this Agreement.

ARTICLE XV

MISCELLANEOUS

     15.1 Assignment.

          (a) Affiliates. Either Party may assign any of its rights or obligations under this Agreement
in any country to its Affiliates and may delegate its obligations under this Agreement in any
country to its Affiliates; provided, however, that such assignment or delegation shall not relieve
the assigning Party of its responsibilities for performance of its obligations under this
Agreement.

          (b) Non-Affiliates. Except as provided in subsection (b)(ii) below, neither Party shall
assign its rights or obligations under this Agreement to a non-Affiliate without the prior written
consent of the other Party, except in connection with a merger or similar reorganization or the
sale of all or substantially all of its assets. This Agreement shall survive any such merger or
reorganization of either Party with or into, or such sale of assets to, another party and no
consent for such merger, reorganization or sale shall be needed; provided, that in the event of
such merger, reorganization or sale, no intellectual property rights of the acquiring corporation
shall be included in the technology licensed hereunder.

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 56.

 

          (c) Party’s Right to Assign Rights to Receive Payment. Either Party may assign its rights to
receive payments hereunder to a Third Party or grant a security interest in its rights to receive
payments hereunder.

          (d) Benefit to Successors. This Agreement shall be binding upon and inure to the benefit of
the successors and permitted assigns of the Parties. Any assignment not in accordance with this
Agreement shall be void.

     15.2 Retained Rights. Nothing in this Agreement shall limit in any respect the right of
either Party to conduct research and development and to market products using such Party’s
technology other than as herein expressly provided.

     15.3 Consents Not Unreasonably Withheld or Delayed. Whenever provision is made in this
Agreement for either Party to secure the consent or approval of the other, that consent or approval
shall not unreasonably be withheld or delayed, and whenever in this Agreement provision is made for
one Party to object to or disapprove a matter, such objection or disapproval shall not unreasonably
be exercised, even when not so expressly stated.

     15.4 Force Majeure. Neither Party shall lose any rights hereunder or be liable to the other
Party for damages or losses on account of failure of performance by the defaulting Party if the
failure is occasioned by government action, war, fire, explosion, flood, strike, lockout, embargo,
act of God, or any other similar cause beyond the control of the defaulting Party, provided that
the Party claiming force majeure has exerted all reasonable efforts to avoid or remedy such force
majeure and has given the other Party prompt notice describing such event, the effect thereof and
the actions being taken to avoid or remedy such force majeure; provided, however, that in no event
shall a Party be required to settle any labor dispute or disturbance.

     15.5 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry
out the purposes and intent of this Agreement.

     15.6 No Trademark Rights. Except as otherwise provided herein, no right, express or implied,
is granted by the Agreement to use in any manner any name or any trade name or trademark of the
other Party or its Affiliates in connection with the performance of this Agreement.

     15.7 Notices. All notices hereunder shall be in writing and shall be deemed given if
delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered
or certified mail (return receipt requested), postage prepaid, or sent by express courier service,
to the Parties at the following addresses (or at such other address for a Party as shall be
specified by like notice; provided that notices of a change of address shall be effective only upon
receipt thereof).

	 	 	 	 	 
	If to GTx:	 

	 	 	[ * ]
	With a copy to:
	 

	 	 	[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 57.

 

	 	 	 	 	 
	If to Ipsen:
	 

	 	 	[ * ]
	With a copy to:
	 

	 	 	[ * ]

     15.8 Waiver. Except as specifically provided for herein, the waiver from time to time by
either of the Parties of any of their rights or their failure to exercise any remedy shall not
operate or be construed as a continuing waiver of same or any other of such Party’s rights or
remedies provided in this Agreement.

     15.9 Severability. If any term, covenant or condition of this Agreement or the application
thereof to any Party or circumstances shall, to any extent or in any country, be held to be invalid
or unenforceable, then (i) the remainder of this Agreement, or the application of such term,
covenant or condition to Parties or circumstances other than those as to which it is held invalid
or unenforceable, shall not be affected thereby and each term, covenant or condition of this
Agreement shall be valid and be enforced to the fullest extent permitted by law; and (ii) the
Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in
good faith in order to provide a reasonably acceptable alternative to the term, covenant or
condition of this Agreement or the application thereof that is invalid or unenforceable, it being
the intent of the Parties that the basic purposes of this Agreement are to be effectuated.

     15.10 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any
Party, irrespective of which Party may be deemed to have authored the ambiguous provision.

     15.11 Governing Law. This Agreement shall be governed by and interpreted under the laws of
the State of New York, as applied to contracts entered into and performed entirely in New York by
New York residents.

     15.12 Headings. The Sections and paragraph headings contained herein are for the purposes of
convenience only and are not intended to define or limit the contents of said Sections or
paragraphs.

     15.13 Counterparts. This Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     15.14 Entire Agreement; Amendments. This Agreement, including all Exhibits attached hereto,
and all documents delivered concurrently herewith, set forth all the covenants, promises,
agreements, warranties, representations, conditions and understandings between the Parties hereto
and supersede and terminate all prior agreements and understandings between the Parties. There are
no covenants, promises, agreements, warranties, representations, conditions or understandings,
either oral or written, between the Parties other than as set forth herein. No subsequent
alteration, amendment, change or addition to this Agreement shall be binding upon the Parties
hereto unless reduced to writing and signed by the respective authorized officers of the Parties.
This Agreement, including without limitation the exhibits, schedules and attachments hereto, are
intended to define the full extent of the legally enforceable undertakings of the Parties

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 58.

 

hereto, and no promise or representation, written or oral, which is not set forth explicitly
is intended by either party to be legally binding. Both Parties acknowledge that in deciding to
enter into the Agreement and to consummate the transaction contemplated thereby neither Party has
relied upon any statement or representations, written or oral, other than those explicitly set
forth herein.

     15.15 Independent Contractors. The status of the Parties under this Agreement shall be that
of independent contractors. Neither Party shall have the right to enter into any agreements on
behalf of the other Party, nor shall it represent to any person that it has any such right or
authority. Nothing in this Agreement shall be construed as establishing a partnership or joint
venture relationship between the Parties.

     15.16 Currency Exchange. Except as set forth in Section 3.12 of this Agreement, all payments
to be made by Ipsen to GTx shall be made in Euros, to a GTx bank account able to receive Euros.

     IN WITNESS WHEREOF, GTx and Ipsen have caused this Agreement to be executed as of the
Effective Date first written above by their respective officers thereunto duly authorized.

	 	 	 	 	 	 	 
	 

	 	GTx, Inc.	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Signed By:
	 	/s/ Mitchell S. Steiner
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	CEO and Vice Chairman
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	IPSEN Ltd	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Signed By:
	 	/s/ Alistair Stokes
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	Director and Chief Executive Officer
 

	 	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 59.

 

EXHIBITS PROVIDED SEPARATELY

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 60.

 

Table of Contents

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	 
	ARTICLE I
	 	DEFINITIONS	 	 	2	 
	1.1
	 	“Active Ingredient”	 	 	2	 
	1.2
	 	“ADT”	 	 	2	 
	1.3
	 	“ADT Indication”	 	 	2	 
	1.4
	 	“ADT Trial”	 	 	2	 
	1.5
	 	“Affiliate”	 	 	2	 
	1.6
	 	“Agreement”	 	 	2	 
	1.7
	 	“Bundled Product”	 	 	2	 
	1.8
	 	“Business Day”	 	 	2	 
	1.9
	 	“Clinical Studies”	 	 	2	 
	1.10
	 	“Combination Product”	 	 	2	 
	1.11
	 	“Commercialization Activities”	 	 	3	 
	1.12
	 	“Competing Product”	 	 	3	 
	1.13
	 	“Confidential Information”	 	 	3	 
	1.14
	 	“Control” or “Controlled”	 	 	3	 
	1.15
	 	“Cost of Goods Sold” or “COGS”	 	 	3	 
	1.16
	 	“Cover”	 	 	3	 
	1.17
	 	“Data and Market Protection”	 	 	3	 
	1.18
	 	“Developing Party”	 	 	3	 
	1.19
	 	“Dominating Patent”	 	 	3	 
	1.20
	 	“Drug Approval Application”	 	 	4	 
	1.21
	 	“Effective Date”	 	 	4	 
	1.22
	 	“Election” and “Election Fee”	 	 	4	 
	1.23
	 	“EMEA”	 	 	4	 
	1.24
	 	“EU”	 	 	4	 
	1.25
	 	“European Territory”	 	 	4	 
	1.26
	 	“Executive Officers”	 	 	4	 
	1.27
	 	“Fareston”	 	 	4	 

 
 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 -i-

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	 
	1.28
	 	“FDA”	 	 	4	 
	1.29
	 	“FDC Act”	 	 	4	 
	1.30
	 	“FTE”	 	 	4	 
	1.31
	 	“FTE Cost”	 	 	4	 
	1.32
	 	“FTE Rate”	 	 	5	 
	1.33
	 	“Generic”	 	 	5	 
	1.34
	 	“GTx Initial Development”	 	 	5	 
	1.35
	 	“GTx Initial Development
Budget” and “GTx Initial Development Plan”	 	 	5	 
	1.36
	 	“GTx Invention”	 	 	5	 
	1.37
	 	“GTx Know-how”	 	 	5	 
	1.38
	 	“GTx Licenses”	 	 	5	 
	1.39
	 	“GTx Patent”	 	 	5	 
	1.40
	 	“GTx Product Improvement”	 	 	5	 
	1.41
	 	“GTx Territory”	 	 	5	 
	1.42
	 	“IND”	 	 	5	 
	1.43
	 	“Indication”	 	 	6	 
	1.44
	 	“Information”	 	 	6	 
	1.45
	 	“Initial Development”	 	 	6	 
	1.46
	 	“Initial Development Expenses”	 	 	6	 
	1.47
	 	“Initial Development Plan”	 	 	6	 
	1.48
	 	“Initial Election Period”	 	 	6	 
	1.49
	 	“Initial Products”	 	 	6	 
	1.50
	 	“Invention”	 	 	6	 
	1.51
	 	“Ipsen Initial Development”	 	 	6	 
	1.52
	 	“Ipsen Initial Development Plan”	 	 	6	 
	1.53
	 	“Ipsen Invention”	 	 	7	 
	1.54
	 	“Ipsen Know-how”	 	 	7	 
	1.55
	 	“Ipsen Patents”	 	 	7	 
	1.56
	 	“Ipsen Product Improvement”	 	 	7	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 -ii-

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	 
	1.57
	 	“Joint ADT Initial Development Expenses”	 	 	7	 
	1.58
	 	“Joint Development Committee” or “JDC”	 	 	7	 
	1.59
	 	“Joint Initial Development Expenses”	 	 	7	 
	1.60
	 	“Joint Invention”	 	 	7	 
	1.61
	 	“Joint Patent”	 	 	7	 
	1.62
	 	“Joint PIN Initial Development Expenses”	 	 	7	 
	1.63
	 	“Joint Subsequent Development”	 	 	8	 
	1.64
	 	“Joint Subsequent Development Budget”, “Joint Subsequent Development	 	 	 	 
	 
	 	Costs”, “Joint Subsequent Development Plan”	 	 	8	 
	1.65
	 	“Launch Date”	 	 	8	 
	1.66
	 	“Licensed Product”	 	 	8	 
	1.67
	 	“Licensed Trademark”	 	 	8	 
	1.68
	 	“List Price”	 	 	8	 
	1.69
	 	“Major Country”	 	 	8	 
	1.70
	 	“Marketing and Sales Committee”	 	 	8	 
	1.71
	 	“Marketing and Sales Plan”	 	 	8	 
	1.72
	 	“Milestone Event”	 	 	8	 
	1.73
	 	“NDA”	 	 	8	 
	1.74
	 	“Net Sales”	 	 	8	 
	1.75
	 	“Opt-in”	 	 	10	 
	1.76
	 	“Opt-in Information”	 	 	10	 
	1.77
	 	“Opt-in Party”, “Opt-in Payment”, “Opt-in Period”, “Opt-in Period	 	 	 	 
	 
	 	1”, “Opt-in Period 2”, “Opt-in Period 3”, “Opt-in Period 4”, “Opt-in Period	 	 	 	 
	 
	 	5”, “Opt-in Notification” , and “Opt-in Payment”	 	 	10	 
	1.78
	 	“Opt-out Party”	 	 	10	 
	1.79
	 	“Non-Developing Party”	 	 	10	 
	1.80
	 	“Orion”	 	 	10	 
	1.81
	 	“Orion License”	 	 	10	 
	1.82
	 	“Past Initial Development Expenses”	 	 	10	 
	1.83
	 	“Patent”	 	 	10	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-iii-

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	 
	1.84
	 	“Patent Expenses”	 	 	10	 
	1.85
	 	“Phase III Clinical Trial(s)”	 	 	11	 
	1.86
	 	“Phase IIIB Clinical Trial(s)”	 	 	11	 
	1.87
	 	“Phase IV Clinical Trial(s)”	 	 	11	 
	1.88
	 	“PIN”	 	 	11	 
	1.89
	 	“PIN Indication”	 	 	11	 
	1.90
	 	“PIN Trial”	 	 	11	 
	1.91
	 	“Pre-Clinical Studies”	 	 	11	 
	1.92
	 	“Pre Opt-in Development Costs”	 	 	11	 
	1.93
	 	“Pricing and Reimbursement Approval”	 	 	11	 
	1.94
	 	“Primary Endpoint”	 	 	11	 
	1.95
	 	“Product Improvement”	 	 	11	 
	1.96
	 	“Regulatory Agency”	 	 	11	 
	1.97
	 	“Regulatory Approval”	 	 	12	 
	1.98
	 	“Royalty Payment”	 	 	12	 
	1.99
	 	“Royalty Reduction” and “Royalty Reduction Cap”	 	 	12	 
	1.100
	 	“Royalty Term”	 	 	12	 
	1.101
	 	“Safety”	 	 	12	 
	1.102
	 	“SERM”	 	 	12	 
	1.103
	 	“Sole Subsequent Development”	 	 	12	 
	1.104
	 	“SPA”	 	 	12	 
	1.105
	 	“Subsequent Development”	 	 	12	 
	1.106
	 	“Supply Price”	 	 	12	 
	1.107
	 	“Tax”	 	 	12	 
	1.108
	 	“Third Party”	 	 	12	 
	1.109
	 	“Third Party License”	 	 	12	 
	1.110
	 	“Toremifene”	 	 	12	 
	1.111
	 	“UTRF”	 	 	12	 
	1.112
	 	“UTRF License”	 	 	12	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-iv-

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	 
	1.113
	 	“Valid Patent Claim”	 	 	13	 
	1.114
	 	“Withholding Royalty Payments”	 	 	13	 
	ARTICLE II
	 	JOINT DEVELOPMENT COMMITTEE	 	 	13	 
	2.1
	 	Formation of JDC	 	 	13	 
	2.2
	 	Meetings	 	 	13	 
	2.3
	 	Agendas	 	 	13	 
	2.4
	 	Responsibilities of the JDC	 	 	14	 
	2.5
	 	Subcommittees of the JDC	 	 	15	 
	ARTICLE III
	 	LICENSING FEES; MILESTONE PAYMENTS; ROYALTIES; REPORTING	 	 	15	 
	3.1
	 	License Fee, Initial Development Expenses, and Election Fee	 	 	15	 
	3.2
	 	Milestone Payments	 	 	15	 
	3.3
	 	Limitation on Milestone Payments	 	 	17	 
	3.4
	 	Royalty Payments	 	 	17	 
	3.5
	 	Sales by Sublicensees	 	 	21	 
	3.6
	 	Relief From Certain Marketing Obligations.	 	 	21	 
	3.7
	 	Payment of Royalties; Reporting	 	 	22	 
	3.8
	 	Royalty Term.	 	 	22	 
	3.9
	 	[  *  ]	 	 	22	 
	3.10
	 	Ipsen’s Rights Upon Expiration of Royalty Term	 	 	23	 
	3.11
	 	Tax Matters	 	 	23	 
	3.12
	 	Currency	 	 	24	 
	3.13
	 	Payments to or Reports by Affiliates	 	 	24	 
	3.14
	 	Payments by Wire Transfer	 	 	24	 
	ARTICLE IV
	 	DEVELOPMENT AND REGISTRATION	 	 	24	 
	4.1
	 	Development Responsibilities	 	 	24	 
	4.2
	 	Initial Development	 	 	24	 
	4.3
	 	Subsequent Development	 	 	30	 
	4.4
	 	Documentation and Data	 	 	37	 
	ARTICLE V
	 	LICENSES	 	 	38	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-v-

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	 
	5.1
	 	Non-Exclusive Licenses to Conduct Development	 	 	38	 
	5.2
	 	Exclusive License to Conduct Commercialization Activities	 	 	38	 
	5.3
	 	Exclusive License Under Licensed Trademarks	 	 	38	 
	5.4
	 	Sublicensing	 	 	38	 
	5.5
	 	Independent Research	 	 	38	 
	5.6
	 	Obligations With Respect to Competing Products	 	 	39	 
	5.7
	 	Ipsen’s Right of First Negotiation	 	 	39	 
	5.8
	 	GTx’s Right of First Negotiation	 	 	40	 
	5.9
	 	Further Negotiations	 	 	40	 
	ARTICLE VI
	 	COMMERCIALIZATION; REGULATORY COMPLIANCE	 	 	41	 
	6.1
	 	Commercialization and Marketing Responsibilities	 	 	41	 
	6.2
	 	Marketing and Sales Committee	 	 	41	 
	6.3
	 	Marketing and Sales Plan and Reports	 	 	41	 
	6.4
	 	Medical Inquiries	 	 	41	 
	6.5
	 	Regulatory Contact	 	 	42	 
	6.6
	 	Regulatory Compliance	 	 	42	 
	6.7
	 	Commercialization Efforts	 	 	42	 
	6.8
	 	Product Launch.	 	 	43	 
	6.9
	 	Commercialization in European Territory	 	 	44	 
	6.10
	 	Advertising and Promotion	 	 	44	 
	6.11
	 	Additional Support by GTx	 	 	44	 
	ARTICLE VII
	 	SUPPLY OF LICENSED PRODUCT	 	 	44	 
	7.1
	 	Manufacture and Supply of Licensed Product	 	 	44	 
	7.2
	 	Technology Transfer in Event of Termination of Supply by Orion	 	 	44	 
	ARTICLE VIII
	 	CONFIDENTIALITY	 	 	45	 
	8.1
	 	Confidentiality Exceptions	 	 	45	 
	8.2
	 	Authorized Disclosure	 	 	45	 
	8.3
	 	Survival	 	 	46	 
	8.4
	 	Publications	 	 	46	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-vi-

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	 
	8.5
	 	Public Disclosures	 	 	46	 
	ARTICLE IX
	 	OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS	 	 	47	 
	9.1
	 	Ownership	 	 	47	 
	9.2
	 	Invention Disclosures	 	 	47	 
	9.3
	 	Disclosure of Provisional and Non-Provisional Patent Applications	 	 	47	 
	9.4
	 	Patent Filings	 	 	47	 
	9.5
	 	Third Party Patent Rights	 	 	49	 
	9.6
	 	Enforcement Rights	 	 	49	 
	9.7
	 	Allocation of Patent Expenses	 	 	50	 
	9.8
	 	Assignment of Joint Patents	 	 	50	 
	9.9
	 	Trademarks	 	 	50	 
	ARTICLE X
	 	REPRESENTATIONS AND WARRANTIES	 	 	51	 
	10.1
	 	Representations and Warranties	 	 	51	 
	10.2
	 	Performance by Affiliates	 	 	53	 
	ARTICLE XI
	 	INFORMATION AND REPORTS	 	 	53	 
	11.1
	 	Information and Reports During Development and Commercialization	 	 	53	 
	11.2
	 	Complaints	 	 	53	 
	11.3
	 	Safety Data Exchange Agreement	 	 	53	 
	11.4
	 	Records of Revenues and Expenses	 	 	53	 
	ARTICLE XII
	 	TERM AND TERMINATION	 	 	54	 
	12.1
	 	Term	 	 	54	 
	12.2
	 	Termination for Material Breach	 	 	54	 
	12.3
	 	Termination by Ipsen	 	 	56	 
	12.4
	 	Bankruptcy	 	 	56	 
	12.5
	 	Effect of Termination by GTx Under Section 12.2 of this Agreement or	 	 	 	 
	 
	 	Termination by Ipsen Under Section 12.3 of this Agreement	 	 	56	 
	12.6
	 	Permitted or compulsory assignment other than to Affiliate or by	 	 	 	 
	 
	 	merger or reorganization	 	 	57	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-vii-

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 
	 	 	 	Page
	12.7
	 	Surviving Rights	 	 	58	 
	ARTICLE XIII
	 	INDEMNIFICATION	 	 	58	 
	13.1
	 	Ipsen and GTx	 	 	58	 
	13.2
	 	Ipsen	 	 	58	 
	13.3
	 	GTx	 	 	59	 
	13.4
	 	Procedure	 	 	59	 
	13.5
	 	Insurance	 	 	59	 
	ARTICLE XIV
	 	DISPUTE RESOLUTION	 	 	60	 
	14.1
	 	Disputes	 	 	60	 
	14.2
	 	Disputes Referred First to Executive Officers	 	 	60	 
	14.3
	 	Resolution of Dispute by Alternate Means	 	 	60	 
	14.4
	 	Patent and Trademark Dispute Resolution	 	 	61	 
	14.5
	 	Injunctive Relief	 	 	61	 
	ARTICLE XV
	 	MISCELLANEOUS	 	 	61	 
	15.1
	 	Assignment	 	 	61	 
	15.2
	 	Retained Rights	 	 	62	 
	15.3
	 	Consents Not Unreasonably Withheld or Delayed	 	 	62	 
	15.4
	 	Force Majeure	 	 	62	 
	15.5
	 	Further Actions	 	 	62	 
	15.6
	 	No Trademark Rights	 	 	62	 
	15.7
	 	Notices	 	 	62	 
	15.8
	 	Waiver	 	 	63	 
	15.9
	 	Severability	 	 	63	 
	15.10
	 	Ambiguities	 	 	63	 
	15.11
	 	Governing Law	 	 	63	 
	15.12
	 	Headings	 	 	63	 
	15.13
	 	Counterparts	 	 	64	 
	15.14
	 	Entire Agreement; Amendments	 	 	64	 
	15.15
	 	Independent Contractors	 	 	64	 
	15.16
	 	Currency Exchange	 	 	64	 

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 -viii-

 

EXHIBIT A

Patents & Patent Applications Controlled by GTx, Inc.

in the European Territory which cover the Licensed Products

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

1

 

EXHIBIT
A (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

2

 

EXHIBIT B

European Community Trademark Registration

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

3

 

EXHIBIT C

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

4

 

EXHIBIT D

Example Calculation to Clarify Section 3.4

	1.	 	[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

5

 

EXHIBIT
E

ADT
DEVELOPMENT PLAN

	[ * ]	 	

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

6

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

7

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

8

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

9

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

10

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

11

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

12

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

13

 

EXHIBIT E (Continued)

[ * ]

	 	 	 
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

14

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

15

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

16

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

17

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

18

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

19

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

20

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

21

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

22

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

23

 

EXHIBIT
E (Continued)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

24

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

25

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

26

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

27

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

28

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

29

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

30

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

31

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

32

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

33

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

34

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

35

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

36

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

37

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

38

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

39

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

40

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

41

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

42

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

43

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

44

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

45

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

46

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

47

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

48

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

49

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

50

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

51

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

52

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

53

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

54

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

55

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

56

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

57

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

58

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

59

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

60

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

61

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

62

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

63

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

64

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

65

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

66

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

67

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

68

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

69

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

70

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

71

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

72

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

73

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

74

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

75

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

76

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

77

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

78

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

79

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

80

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

81

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

82

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

83

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

84

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

85

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

86

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

87

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

88

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

89

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

90

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

91

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

92

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

93

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

94

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

95

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

96

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

97

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

98

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

99

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

100

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

101

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

102

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

103

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

104

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

105

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

106

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

107

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

108

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

109

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

110

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

111

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

112

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

113

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

114

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

115

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

116

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

117

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

118

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

119

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

120

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

121

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

122

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

123

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

124

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

125

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

126

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

127

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

128

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

129

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

130

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

131

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

132

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

133

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

134

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

135

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

136

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

137

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

138

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

139

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

140

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

141

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

142

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

143

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

144

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

145

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

146

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

147

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

148

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

149

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

150

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

151

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

152

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

153

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

154

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

155

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

156

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

157

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

158

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

159

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

160

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

161

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

162

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

163

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

164

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

165

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

166

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

167

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

168

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

169

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

170

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

171

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

172

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

173

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

174

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

175

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

176

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

177

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

178

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

179

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

180

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

181

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

182

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

183

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

184

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

185

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

186

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

187

 

EXHIBIT E (cont.)

[ * ]

 

			
	[ * ]	 	= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

188Ex-(10)(b)

 

Exhibit (10)(b)

     As previously described in Wachovia’s proxy statement for the 2006 annual meeting of shareholders,
Wachovia maintains a compensation arrangement with Ernest S. Rady, a director of Wachovia elected
at the 2006 annual meeting of shareholders. The compensation arrangement relates to Mr. Rady’s
employment at Wachovia following Wachovia’s acquisition of Westcorp on March 1, 2006 (at which time
Mr. Rady was not a director of Wachovia). As a Wachovia employee, Mr. Rady is not separately
compensated for his services as a director. Attached hereto is information about Mr. Rady’s
compensation arrangement with Wachovia.

 

 

	•	 	Chairman of Wachovia’s dealer finance business

	 	•	 	As Chairman of our dealer finance business, you will be the most senior
executive in our company with respect to issues relating to indirect consumer
automobile financing and auto dealer floor plan lending.
	 
	 	•	 	As such, we will look to you for direction on major strategy and policy
issues.
	 
	 	•	 	Tom Wolfe, who will be responsible for the day-to-day operation of the
dealer finance business, and Carlos Evans, who is Wachovia’s Wholesale Segment
leader and who will be Tom’s supervisor, will provide monthly business unit review
updates to you and keep you apprised of any major issues affecting Wachovia’s
automobile and dealer finance business.

	•	 	Chairman of Wachovia’s California banking business.

	 	•	 	As Chairman of Wachovia’s California’s banking business, you will be
Wachovia’s senior executive in California and will be asked to provide counsel to
Wachovia’s operational executives regarding Wachovia’s strategy for expanding our
general banking business in California, including potential acquisitions.
	 
	 	•	 	Chairman of a commercial lending committee that will look at loan
exposures in excess of a designated amount.
	 
	 	•	 	As is the case with the dealer finance business, Wachovia’s general
banking leadership in California will provide monthly business unit review updates
to you and keep you apprised of any major issues affecting Wachovia’s general
banking business in California.
	 
	 	•	 	Due to your extensive business contacts in California, Wachovia would
also ask for your assistance in business development opportunities for our
commercial real estate and commercial lending businesses.

	•	 	Reporting to Ben Jenkins, Head of Wachovia’s General Banking Group

	•	 	Compensation

	 	•	 	Base Salary for 2006 and 2007 — $500,000
	 
	 	•	 	Incentive Compensation for 2006 and 2007 — minimum of $275,000.
Eligible for additional incentive compensation under Wachovia Corporation Senior
Management Incentive Plan.
	 
	 	•	 	Subject to termination for cause or voluntary resignation
	 
	 	•	 	Two years severance under terms set forth above if terminated without
cause prior to January 1, 2008
	 
	 	•	 	Upon payroll and benefits conversion, you will also be eligible to
participate in Wachovia’s employee benefits plans, including stock option plans, to
the same extent as other similarly situated senior executives

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]